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Dysregulation of peptide-activated pathways causes a range of diseases, fostering the 
discovery and clinical development of peptide drugs. Many endogenous peptides activate G 
protein-coupled receptors (GPCRs) — nearly fifty GPCR peptide drugs have been approved 
to date, most of them for metabolic disease or oncology, and more than 10 potentially first-
in-class peptide therapeutics are in the pipeline. The majority of existing peptide therapeutics 
are agonists, which reflects the currently dominant strategy of modifying the endogenous 
peptide sequence of ligands for peptide-binding GPCRs. Increasingly, novel strategies are 
being employed to develop both agonists and antagonists, and both to introduce chemical 
novelty and improve drug-like properties.  Pharmacodynamic improvements are evolving to 
bias ligands to activate specific downstream signalling pathways in order to optimise efficacy 
and reduce side effects. In pharmacokinetics, modifications that increase plasma-half life 
have been revolutionary. Here, we discuss the current status of peptide drugs targeting 




G protein-coupled receptors (GPCRs) mediate a wide range of signalling processes and are 
targeted by one third of drugs in clinical use1. Although most GPCR-targeting therapeutics 
are small molecules2, the endogenous ligands for many GPCRs are peptides (comprising 50 




GPCRs are divided into families based on structural similarities. The largest group is the 
Class A (rhodopsin-like) family, followed by the Class B (secretin) family. Although other 
families, such as the Class C, frizzled, and adhesion classes exist, therapeutics 
predominantly target Class A and B GPCRs, so this Review is focussed on these two 
groups. The International Union of Basic and Clinical Pharmacology (IUPHAR) Guide to 
Pharmacology3 currently lists 197 Class A receptors with known ligands (excluding olfactory, 
vision, taste and vomeronasal sensory receptors); 64 (32%) of these bind to endogenous 
peptides3. In GPCR Class B, there are 20 receptors activated by 15 endogenous peptides. 
These GPCRs are grouped in the following families based on which ligand they bind: 
calcitonin, corticotropin-releasing factor, glucagon, parathyroid hormone (which is generally 
considered to be a peptide, despite its 84-amino acid length), or vasoactive intestinal peptide 
(VIP) or pituitary adenylate cyclase-activating peptide (PACAP). 
A further 87 'orphan' receptors from different families — for which the endogenous ligand is 
not yet known — have been identified in the human genome. For 54 of these orphans, at 
least one publication has proposed an endogenous ligand, some of which are peptides4. 'De-
orphanisation' of these receptors is ongoing. For example, G protein-coupled receptor 171 
(GPR171) and GPR83 were recently found to interact with the neuropeptides PEN and LEN 
respectively, which are abundant in mouse brain (and highly conserved in humans). Initial 
studies suggest they may be functionally coupled in the regulation of feeding, and if 
substantiated, these receptors could be new potential drug targets5,6. 
Endogenous peptides that bind to GPCRs on cell surfaces spatiotemporally span 
paracrine and autocrine signalling, from long-acting hormones to locally released mediators 
of cellular functions and neurotransmitters. Peptides are one of the largest and most ancient 
classes of intercellular chemical messengers7. The pioneering development, using these 
naturally occurring peptides as therapeutics, was the use of insulin in the 1920s. Insulin 
principally targets a tyrosine kinase receptor8 and the development of this therapeutic 
exploited the remarkable pharmacodynamic properties of peptides: high affinity, selectivity 
and potency. In line with the observed effects of insulin, most other peptide therapies are 
well tolerated with few off-target effects. 
Naturally occurring peptides, however, do not typically make good therapeutics. The 
development of peptides as drugs has been limited by poor pharmacokinetics (short half-life, 
rapid degradation and high levels of clearance) and a lack of oral bioavailability due to a 
combination of low gastrointestinal stability and poor permeability. Therefore, strategies 
need to be developed to address these aspects before most peptides can be effective 
medicines. 
Peptide drugs occupy a structural space between biologics (antibodies and proteins) 
and small molecules. Whereas endogenous signalling peptides have usually 50 or fewer 
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residues, the FDA defines peptide drugs9 as having a maximum of 40 residues (a few 
exceptions have been noted), not limited to the 20 genetically encoded amino acids. These 
therapeutics are undergoing a renaissance. Emerging novel strategies include half-life 
extension platforms, stapling and resistance to proteolysis, all of which significantly improve 
pharmacokinetics and oral bioavailability.  These strategies are perhaps best exemplified by 
the development of glucagon-like peptide 1 (GLP-1) receptor agonists that have increased 
resistance to proteolytic degradation and reduced renal clearance. Several successfully 
marketed products and a multitude of pre-clinical novel approaches (e.g., stapling, 
cyclization, and glycosylation) have come from these efforts. This success has also fostered 
the development of multifunctional peptides that combine agonism for two or more GPCRs in 
the same peptide, based on relatively high sequence homology and similar binding sites. 
Complimentary pharmacodynamic strategies are extending the repertoire of drugs that act at 
a given GPCR.  
Peptide ligands that can selectively activate downstream signalling pathways and are 
described as biased towards, for example, G proteins or β-arrestins (the two main pathways 
downstream of GPCRs), are also emerging.  These pathways may be linked to distinct 
physiological or pathophysiological responses — beneficial or detrimental — so biased 
ligands can be designed to have the optimum therapeutic activity but with reduced side 
effects or receptor internalisation. 
The application of structure-based design has significantly altered all aspects of small 
molecule drug discovery, including drugs targeting GPCRs10, 11.  Peptides are also amenable 
to structure-based design strategies. X-ray crystallography or cryo-electron microscopy 
(cryo-EM) [G] structures of the binding domains of over 27 peptide-binding or protein-
binding GPCRs have been reported  — amongst these 65 unique receptor–ligand 
complexes, 22 contain a peptide ligand. The rapidly expanding repertoire of receptor 
structures will substantially advance understanding of the basic peptide–receptor structure 
activity relationship (SAR) and more subtle aspects of conformational biased signalling, 
thereby enabling rational agonist or antagonist design to activate or block a 
pathophysiological process. 
In this Review, we discuss the clinically approved and preclinical GPCR-targeting 
peptide therapeutics (Figure 1) and outline the challenges in the field. We also highlight key 
strategies to improve pharmacokinetics (mainly via increases in plasma half-life) and 
pharmacodynamics (via increased potency), as well as ligand bias. 
 
Approved peptide therapeutics 
The majority of GPCR-targeting peptide drugs that are either approved for clinical use or in 
development function as agonists, and are used to replace or enhance low levels of 
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endogenous peptides. In Class A, major receptor targets include μ and κ opioid receptors 
(abbreviated to MOR and KOR, respectively) to relieve pain; oxytocin and vasopressin 
receptors for induction of labour; and apelin and angiotensin receptors in cardiovascular 
disease (Table 1, Table 2).  More specialised targets include the somatostatin receptor for 
acromegaly and Cushing’s disease. Peptide therapies targeting Class B receptors are 
dominated by GLP-1 receptor agonists for the treatment of type 2 diabetes (T2D), along with 
synthetic or modified versions of peptide hormones. 
Few antagonists have made it to the clinic. Most of those that have made this leap 
target Class A GPCRs. Antagonists that block the action of gonadotrophin releasing 
hormone, such as Degarelix and Abarelix, or agonists that desensitise the receptor to have 
the same effect, such as Buserelin, are used for the treatment of cancer. 
 
Synthetic endogenous peptide analogues 
Oxytocin12, 13 and vasopressin were the first chemically synthesised variants of endogenous 
peptides for Class A receptors to enter clinical use, and did so in the 1950s. These two 
peptides are amongst the ten peptides that are usually synthesised chemically or by 
recombinant technology, but that have an identical sequence to their endogenous peptide 
equivalents, that have been approved for clinical use in one or more countries (Table 1). 
Evaluation of those ten peptides provides an opportunity to examine the properties of native 
peptides that may limit or enable their widespread therapeutic application as well as the 
impact of those properties on drug development strategies. 
Peptides targeting Class A GPCRs are mainly agonists that bind with both high 
affinity (median –log of the dissociation constant (pKi) = 8.4) and potency (median –log of the 
half maximal effective concentration (pEC50) = 8.5), compared with the average clinically 
used drug14.  However, they typically demonstrate very short plasma half-lives following 
intravenous administration, with a median value of ~5.3 minutes, reflecting their rapid 
degradation by peptidases and/or high rates of excretion, particularly by the kidney. 
Theoretically, peptide levels will have therefore declined to <1% of the original dose within 6 
half-lives, which is about 32 minutes. Consistent with their polar, hydrophobic chemical 
properties, they have low median volumes of distribution (~9.8 litres, which is close to the 
expected total volume of interstitial fluid), indicating that the protein is restricted to the fluid 
compartment with negligible distribution into tissues.  Finally, endogenous peptides typically 
have low protein plasma binding, which ensures that the majority of the circulating peptide is 
in the unbound state and available to directly bind to and activate its cognate receptor.  
However, unbound peptide is also highly susceptible to renal elimination and cleavage by 
serum or tissue proteases; both of these processes decrease plasma half-lives. 
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The endogenous ligands for all Class B GPCRs are peptides. For peptides that 
interact with Class B GPCRs, the median pharmacodynamic and pharmacokinetic values 
are similar to those for peptides that target Class A receptors: high potency (pEC50 = 9.9) 
combined with short plasma half-life (15 minutes) and low volume of distribution (~9.9 litres). 
Calcitonin (isolated from salmon in the 1970s) was one of the first native peptides to be used 
clinically, and was used to treat Paget’s disease in patients who were unresponsive to first-
line treatments. Human calcitonin is used in patients who develop antibodies to the salmon 
calcitonin. The goal of treatment is to inhibit bone resorption by osteoclasts and therefore 
increase bone mass15. 
Paradoxically, at least some of the peptides in both classes are likely successful 
because their short plasma half-lives, which is usually an undesirable trait, are exploited for 
clinical benefit.  At one extreme, the peptide therapeutic with the shortest half-life is 
angiotensin II, first synthesised in 1947 but only approved in 2017 (as Giapreza).  This 
synthetic analogue of angiotensin II is used for the treatment of critically ill patients with 
septic shock, in whom an abnormal distribution of blood to the smallest blood vessels results 
in inadequate systemic blood supply, which can be fatal.  The drug binds to vascular smooth 
muscle AT1 receptors and takes a median time of five minutes to adequately increase blood 
pressure following intravenous dosing16. The short half-life — less than one minute — 
ensures that hypertension resulting from an overdose is very unlikely. Similarly, oxytocin, 
which was sequenced and synthesised in the 1950s13,14, is used to induce labour and 
strengthen contractions immediately after intravenous administration, but then subsides 
within an hour, reflecting its short half-life of a few minutes. 
 
Modified peptides 
Twenty six synthetic peptides (20 agonists and six competitive antagonists) targeting eight 
Class A receptor families have been approved for clinical use (Table 2). The few antagonists 
that have been developed (such as Icatibant and Cetrorelix) usually have sub-nanomolar 
affinity, which is higher than the affinity of the endogenous peptide.  This may be an 
important requirement for a clinically successful peptide antagonist, given the high potency 
and affinity of the endogenous peptide agonists, suggesting that effective antagonists 
require high levels of receptor occupancy to maintain efficacy. In this regard, peptides 
targeting the gonadotrophin-releasing hormone (GnRH) receptor in the pituitary are 
particularly intriguing in the non-steroidal manipulation of the reproductive endocrine axis.  
For example, the agonist Buserelin acts by an unusual pharmacological mechanism as it 
desensitises the GnRH receptor, reducing the amount of gonadotropin released from the 
pituitary gland, thereby inhibiting testosterone secretion in males and oestrogen secretion in 
females. Therefore, this agonist peptide effectively switches off the GnRH receptor by 
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removing receptors from the cell surface and reducing further stimulation.  Whereas 
transient administration of Buserelin — for example, in the setting of in-vitro fertilization —
suppresses the premature surge of luteinizing hormone, there are unwanted side effects 
caused by the initial agonist activity of this peptide, such as hyperstimulation of the ovaries, 
which has led to the development of GnRH receptor antagonists such a Ganirelix (Figure 
2)17.  To date, no peptide inverse agonists or allosteric modulators have been reported in 
clinical use; most of the current drugs are based on endogenous peptides and therefore bind 
to the orthosteric site. 
In Class B, all 13 existing therapeutics are agonists that target one of three receptor 
families (principally the GLP-1 receptor in the glucagon family), and, like Class A-targeting 
synthetic peptides, have a high median affinity and potency (pKi = 8.9; pEC50 = 9.7) and a 
comparatively low volume of distribution (~16 litres) following subcutaneous injection.  The 
median plasma half-life is around one hour (but this value excludes peptides modified 
specifically to have very long half-lives, measured in days), which has been achieved by a 
combination of selective amino acid substitutions at known sites of enzymatic cleavage and 
conjugation to ligands that bind serum proteins, such as albumin, which protects the 
peptides from enzymatic cleavage and reduces renal clearance18-22. 
Plasma protein binding of the remaining synthetic peptides in Table 2 is, in many 
cases, also high despite a lack of specific modifications that link the peptides to plasma 
proteins. According to the free drug hypothesis, only unbound drug is available to bind to 
and act at physiological sites of action. Therefore, plasma protein binding can influence both 
pharmacodynamic effects and pharmacokinetic properties of peptides.  Liu et al.23 have 
argued that, because many small molecule drugs (~30%) have high plasma binding, this is 
not necessarily an undesirable trait.  Smith et al.24 have maintained that increasing plasma 
binding, which increases metabolic stability and reduces clearance by organs such as the 
kidney, will lead to better drugs.  The effects of plasma binding on the elimination (and 
therefore half-life) of peptides can be complex.  For peptides excreted in their intact form by 
renal glomerular filtration (such as Cetrorelix, 86% of which is plasma-bound), increasing 
plasma binding would be expected to decrease the rate of elimination, because only the free 
peptide is filtered. Conversely, Buserelin (15% of which is plasma-bound) is metabolised by 
proteolytic enzymes; therefore, reducing proteolytic cleavage is expected to have a greater 
effect than increasing plasma protein binding on plasma exposure (Table 2). 
 
Lessons from recent clinical approvals 
During the last three years, 16 of the 195 FDA-approved new drugs were peptides25,26,27. 
Abaloparatide, which was approved for post-menopausal osteoporosis in 2017, was the first 
analogue of human parathyroid hormone-related protein to be developed. Although this 
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molecule is distinct from Teriparatide (a parathyroid hormone analogue), both of them target 
the PTH1 receptor for the same clinical condition and have similar side effects; however, 
Abaloparatide induces a greater increase in bone density28. Abaloparatide binds to the 
receptor with an affinity that is two orders of magnitude higher than that of Teriparatide. In 
addition, Abaloparatide binds with higher selectivity to a G protein-dependent receptor 
conformation (called RG), which results in transient responses and favours bone-formation 
versus a second confirmation (called R0), which is comparatively prolonged and favours 
unwanted bone-resorption29; R0 is bound by parathyroid hormone and analogues such as 
Teriparatide. 
2017 also saw the approval of Semaglutide30, the fifth GLP-1 receptor agonist to be 
approved for T2D. Of note, Semaglutide is one of several drugs that has a significantly 
increased half-life, around 168 hr. This increase was achieved by using a free fatty acid 
linker that allows the molecule to form a non-covalent reversible interaction with albumin, 
which reduces renal excretion. A different protein-linking strategy was used in the design of 
Albiglutide and Dulaglutide. These two GLP-1 receptor agonists become covalently linked 
(irreversibly) to large proteins; albumin and an Fc fragment of human IgG4, respectively. 
Importantly, an α-aminobutyric acid was engineered into Semaglutide at position 8 to reduce 
metabolism by dipeptyl peptidase 4 (DPP4), a cell-surface protein that cleaves numerous 
circulating peptides. The GLP-1 sequence in position 8 of Albiglutide has also been modified 
by substituting glycine for alanine adjacent to the DPP4 hydrolysis site to reduce 
metabolism. Modifications to GLP-1 receptor agonists have led to substantial increases in 
plasma half-lives, reducing the frequency of dosing from twice daily to weekly, which should 
improve patient compliance. 
Although it does not target a GPCR, Plecanatide, an engineered peptide agonist of 
guanylate cyclase C, is notable in that it is administered orally and acts directly in the 
gastrointestinal tract, demonstrating that local targeting approaches are feasible for 
intestinally restricted targets. GPCRs are abundant in the gut, so this could provide a novel 
approach for future therapeutic strategies.  
Other peptide therapeutics have been approved for novel indications or uses. In 
2018, the second melanocortin agonist, Bremelanotide, was approved, but the approval was 
for a new clinical indication, sexual arousal disorder31. Lutathera (lutetium Lu 177 dotatate) 
was also approved in 2018 for the treatment of neuroendocrine tumours and is the most 
recent example of a peptide receptor radionuclide therapy. In this compound, the peptide 
DOTATATE, a somatostatin receptor agonist, is labelled with lutetium-177. After binding to 
somatostatin receptors, which are found at a high density on the surface of tumours, the 
radiation emitted by the peptide causes tumour cell death but, owing to the limited particle 
range, it causes little toxicity to adjacent healthy tissue32. 
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In 2019, Difelikefalin was approved as a ‘first-in-class’ κ-opioid receptor (KOR) 
agonist that has a high degree of selectivity for KOR over other opioid receptors and is used 
in the treatment of pain after abdominal surgery.  Importantly, there are few of the CNS side 
effects such as sedation, dysphoria, and hallucinations that are associated with small 
molecule analgesics33.  This is consistent with the little or absent CNS permeability observed 
for Difelikefalin and is an example of a therapeutic for which lack of brain penetrance, as 
often occurs with peptides, is an advantage over a small molecule.  Development of 
compounds selective for peripheral KORs is crucial for managing pain in the context of the 
emerging opiate crisis. 
 
Peptides in the pipeline 
Phase 3 
Three of the peptides currently in Phase 3 development are potentially first-in-class (Table 
3).  BL-8040 is the first peptide antagonist for C-X-C chemokine receptor type 4 (CXCR4) 
and, if it progresses to clinic, BL-8040 would compete with an established small molecule 
antagonist (Plerixafor) for the same clinical indication – the mobilisation of hematopoietic 
stem cells to peripheral blood prior to collection for autologous cell transplantation34. The 
interaction between the chemokine CXCL12 (also known as stromal cell-derived factor 1, 
SDF1) and its receptor, CXCR4, plays a key role in hematopoietic stem cell mobilization. 
Livoletide is a first-in-class analogue of unacylated ghrelin (UAG) and is being 
evaluated for the treatment of Prader–Willi syndrome, a rare genetic disease, to reduce 
hyperphagia (excessive eating) and obesity35,36.  Ghrelin, the ‘hunger hormone’, stimulates 
appetite, increases food intake and promotes fat storage, all of which are severely 
upregulated in patients with Prader–Willi syndrome. Interestingly, Livoletide is a fully cyclised 
(cyclo(-Ser-Pro-Glu-His-Gln-Arg-Val-Gln) variant, which protects this peptide from 
metabolism (at least in vitro in human blood) and extends plasma half-life35,36. However, the 
exact mechanism of action is still unclear. A number of studies suggest that when UAG is 
co-administered with ghrelin it acts as a functional antagonist or acts via another receptor37. 
Other studies suggest that UAG is a full agonist38, so the data from late-stage clinical trials 
could be informative. 
Setmelanotide39 is proposed as a possible first-in-class MC4 receptor agonist, as it 
has a modest ~20-fold selectivity over the MC3 receptor, which would potentially avoid 
cardiovascular side effects. The MC4 receptor is a key regulator in the hypothalamic control 
of food intake.  The synthetic peptide is in development for the treatment of individuals with 
genetic variants in the pro-opiomelanocortin and leptin receptors, which cause severe early 





In ongoing Phase 2 trials, novel therapeutic strategies are exemplified by EP-100, which 
contains synthetic GnRH, which is 10 amino acids, attached to an eighteen amino acid 
cationic α-helical lytic peptide (CLIP-71) without a linker40. This lytic domain interacts with the 
negatively charged membrane to induce cell death. Cancerous cells overexpress GnRH1 
receptors compared with normal tissue and are therefore thought to bind the GnRH peptide, 
so binding of EP-100 to these receptors would target the lytic CLIP-71 domain preferentially 
to cancer cells. One potential advantage of this strategy is that the lytic peptide does not 
need to be released from GnRH by cleavage of a linker, which avoids possible toxicity. 
Among Class B receptor ligands, the naturally occurring peptide stresscopin 
(urocortin 3) targets the corticotropin-releasing factor CRF2 receptor and has shown short-
term, dose-dependent efficacy in improving cardiac index and systemic vascular 
resistance41. Stresscopin (as RT-400) is in clinical trials for acute decompensated heart 
failure, a major cause of hospitalisation. 
Table 3 also summarises peptides that have been discontinued in Phase 2 or 3 
clinical trials. The reasons why trials have not progressed are often not disclosed in peer 
reviewed papers and are mainly found on the relevant company websites. With this 
important caveat, the predominant reason cited for termination of a trial was futility (the 
inability to achieve a clinical objectives) rather than adverse side effects. In some cases, the 
Phase 3 trials were testing new peptides and clinical indications. For example, foot ulcers 
affects one in four diabetic patients and there is currently an unmet need for new treatments.  
Angiotensin II has been shown to promote would healing42; however, Aclerastide, an 
angiotensin II receptor agonist, failed to meet the primary efficacy endpoint of confirmed 
complete wound closure of the target ulcer within 12 weeks of the start of treatment. For 
others, peptides lacked efficacy against established targets. Terlipressin has been used in 
the treatment of hypotension and septic shock (Table 2) since 2006; surprisingly, in 2018, a 
large (868-patient) phase 2B/3 clinical trial of Selepressin, which targets the same receptors, 
in sepsis43 was terminated early for futility44. 
 
Strategies to improve peptide design 
Potency, half-life and administration 
What pharmacokinetic and pharmacodynamic properties contribute to an efficacious peptide 
drug?  Currently there is no consensus, but a trend is emerging amongst recently approved 
drugs for high sustained target potency combined with increased plasma half-life and 
reduced enzymatic metabolism and renal elimination. Synthetically modified peptides 
targeting Class A GPCRs have maintained a high affinity (median pKi = 8.8), similar to that 
observed for native peptides, but have a substantially increased median plasma half-life (3 
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hours, excluding compounds with flip-flop kinetics [G], compared with ~5 minutes for native 
peptide equivalents). Flip-flop kinetics have also been used to increase plasma half-life. For 
example, Degarelix (Table 2) is a synthetic derivative of GnRH that blocks binding of the 
endogenous peptide to receptors in the pituitary gland, and is used to treat prostate cancer.  
Following subcutaneous administration, Degarelix forms a depot at the site of injection, from 
which the drug is slowly released into circulation to produce a plasma half-life from 42–70 
days.  Clearance is unaffected, and occurs mainly via hydrolysis in the hepatobiliary system 
and excretion of the unchanged drug by the kidney45, 46.  Similarly, Lanreotide, a 
somatostatin agonist that acts mainly by binding to the SST2 and SST5 receptors, and is 
used to inhibit growth hormone release to treat acromegaly, also forms a drug depot at the 
site of injection, giving a plasma half-life of 22 days47, and also contains unnatural amino 
acids (Box 1). 
The majority of peptides that target GPCRs are administered by injection, although 
other routes (for example, intranasal administration is used for Desmopressin) are 
increasingly being exploited. Charged and hydrophilic molecules such as peptides are 
typically not orally bioavailable. After several decades of synthesising modified peptides, the 
inherent disadvantages of low membrane permeability, which limits oral bioavailability and 
tissue distribution, including to the CNS, are still applicable to most peptide drugs. However, 
there are a number of encouraging examples of the application of permeation enhancer 
strategies48 and detailed SARs are being explored, especially for cyclic and conformationally 
constrained peptides49.  The most advanced, and exciting, of these approaches has been 
pioneered by Emisphere using a pharmaceutically inactive small-molecule enhancer N-[8-(2-
hydroxybenzoyl)amino]caprylate (SNAC) co-formulated with Semaglutide (a GLP-1 receptor 
agonist already approved as an injectable for the treatment of T2DM). The resulting drug, 
oral Semaglutide50, had increased transcellular permeability and bioavailability of ~4%51. The 
highest dose tested, 40 mg administered once daily orally, resulted in comparable efficacy to 
1mg Semaglutide injected once weekly52. Oral Semaglutide was approved by the FDA in 
2019. For drugs with high hydrophilicity and poor membrane permeability, such as peptides, 
absorption enhancers can promote membrane permeability and improve oral bioavailability. 
Experimental approaches to enhance brain permeability include linking neurotensin 
to a brain-penetrant peptide, angiopep-2, thereby increasing transport across the blood–
brain barrier via receptor-mediated transcytosis by about ten-fold.  This was sufficient to 
reverse pain behaviours in animal models of neuropathic and bone cancer pain53. 
Desmopressin is one of the few examples of a peptide that can be administered 
orally. Cyclization contributes to its resistance to metabolism, and its hydrophobic nature 
enhances cellular absorption across the gut. Bioavailability is very low by this route (0.08–
0.16%)54 but this level is sufficient to achieve a plasma concentration that is clinically 
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effective in T2D. The success of desmopressin has proven the potential of engineering 
peptides to have oral activity. As a result of the range of strategies outlined above, a main 
area of growth for peptide drugs is in targeting peripheral peptide receptors, particularly 
those linked to metabolic diseases (Table 2). 
 
Strategies for GLP-1 receptor agonists 
The history of the development of GLP-1 receptor agonists exemplifies the broad range of 
approaches used to address the pharmacokinetic challenges in peptide development (Figure 
2, Table 4). To date, seven peptide GLP-1 receptor agonists are approved for the treatment 
of T2D with projected global sales in 2020 of at least US$10bn (see EvaluatePharma in 
Related links). 
GLP-1 has multiple effects that are beneficial in the treatment of T2D. Despite this, 
the natural peptide has a very short plasma half-life (~2 minutes) because of rapid enzymatic 
cleavage and enzymatic inactivation by DPP4, which precludes its use as an effective 
therapeutic treatment. Additional studies confirmed high plasma clearance following the 
subcutaneous route of administration55, 56. 
Exenatide (Table 4) was the first GLP-1 receptor agonist approved for clinical use.  In 
1992, Eng et al.57 identified exendin-4, a new peptide hormone from the saliva of the Gila 
monster (Heloderma suspectum).  Exendin-4 had many of the same pharmacological 
properties as GLP-1 — it increased insulin secretion and reduced plasma glucose levels.  
However, unlike GLP-1, exendin-4 is resistant to cleavage and inactivation by DPP4.  
Exendin-4, as Exenatide, received approval for the treatment of T2D in 2005 as an 
adjunctive therapy and in 2009 as a monotherapy58. Although Exenatide has been widely 
used for the treatment of T2D, its short plasma half-life requires frequent (twice daily) 
subcutaneous injection, which limits efficacy, results in poor patient compliance and 
increases the risks of additional side effects, such as infection at the sites of injection. 
Following the success of Exenatide, multiple strategies were employed to increase 
plasma stability and half-life, reduce renal elimination and improve oral bioavailability for 
GLP-1 receptor agonists. These strategies can be broadly divided into two approaches.  One 
is based around extending the plasma half-life of Exenatide, leading to Exenatide once 
weekly (QW) and Lixisenatide. Exenatide QW59 is a reformulation of Exenatide into 
microspheres consisting of a biodegradable polymer, poly-(D,L-lactide-co-glycolide), to 
extend the dosing interval to weekly administration. In Lixisenatide60, modification of the 
Exenatide sequence, including addition of a C-terminal lysine tail, conferred resistance to 
DPP4 cleavage and increased plasma half-life. 
The other strategy focused on modifying the native GLP-1 peptide, leading to 
Liraglutide, Albiglutide, Dulaglutide and, most recently, Semaglutide (Figure 2, Table 4). 
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Because of the short half-life of native GLP-1, as a direct result of both cleavage by DPP4 
and rapid renal elimination owing to its relatively small size, a combination of strategic 
solutions has been employed.  Liraglutide61 was approved in 2009 and is a human GLP-1 
receptor agonist based on the native GLP-1 peptide with one amino acid substitution 
(Lys24Arg) and a C16 palmitic acid side chain attached via a glutamyl spacer at position 26.  
These modifications increase its binding to serum albumin, which significantly reduces renal 
elimination and DPP4 cleavage.  The active modified GLP-1 is released from albumin at a 
slow, constant rate, resulting in slower degradation and reduced renal elimination compared, 
for example, to that of the mature endogenous form of GLP-1, GLP-17-37. Semaglutide62, 
which was approved in 2017, incorporates the unnatural amino acid α-aminoisobutyric acid 
(Box 1) at position 8 to reduce DPP4 cleavage and contains an alternative C18 fatty diacid at 
Arg26, which provides strong albumin binding.  Albiglutide22 and Dulaglutide63 are variants of 
peptide fusion proteins. Both are protected from DPP4 cleavage because of substitutions at 
position 8 and both contain 2 copies of GLP-1, fused to either human serum albumin 
(Albiglutide) or covalently linked to a human IgG4-Fc heavy chain by a small peptide linker 
(Dulaglutide), to increase the half-life of the molecule owing to recycling by the neonatal Fc 
receptor (FcRn) and/or increased molecular weight. 
All of these GLP-1 receptor agonists require subcutaneous administration.  However, 
several promising oral delivery approaches are in various stages of development, including 
the recently approved oral Semaglutide, which is co-formulated with SNAC as described in 
the section on potency, half-life and administration. 
 
Ligand bias 
Traditional drug–receptor theory posits that drugs have two properties: affinity and intrinsic 
efficacy.  Affinity is the quantifiable measure of how tightly a drug binds to its target and is 
constant for each drug–receptor pair, supporting medicinal-chemistry-led SAR investigations 
and the application of concepts such as drug selectivity for target over non-target receptors.  
However, affinity says nothing about the functional consequences of a drug–receptor 
interaction.  This is defined by the term ‘intrinsic efficacy’, which describes the effect a drug 
has on receptor activity.  Using this original definition, drugs are either agonists (with a 
combination of affinity and intrinsic efficacy) or antagonists (with affinity but no intrinsic 
efficacy), an approach that has underpinned drug development for the past few decades.  
However, there is increasing evidence that simple concepts of agonism and antagonism only 
scratch the surface of the drug–receptor signalling landscape.  We now know that receptors 
adopt a range of conformational states, thus giving rise to important new pharmacological 
concepts such as constitutive activity and biased signalling (or functional selectivity).  
Because of their relatively large size, peptides often interact at multiple key positions within 
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both the extracellular and transmembrane domains of GPCRs.  These contemporary 
pharmacological concepts may have major implications in the design and optimisation of 
new peptide drugs, especially when used in combination with the structural biology 
techniques described later in this article. 
A receptor may be able to engage with a spectrum of downstream signalling 
pathways, but a ligand with affinity for that receptor may affect only a subset of these 
pathways, and may be an agonist of some and an antagonist of others. This observation 
underpins the concept of ligand bias and is the definition of a biased peptide ligand used in 
this review.  This principle has been used as a criterion to identify biased peptides from the 
literature (see Box 2).  Bias is usually examined in the context of the two most thoroughly 
characterised GPCR signalling pathways, those initiated by the binding of β-arrestin or G 
proteins to the GPCR complex. Importantly, however, biased signalling can refer to any 
signalling pathway measured, for example those involving different subtypes of G proteins, 
and can be considered to be specific to both the context and the pathway.  As such, multiple 
drugs acting at a single receptor may all be characterised as agonists, but each may have a 
different functional selectivity profile for the cellular pathways regulated by that receptor. 
How important is bias in a particular pathway?  Physiologically, this is exemplified 
with the GnRH1 receptor, which is unusual amongst the peptide-binding GPCRs because it 
lacks the C-terminal intracellular domain.  Prolonged agonist stimulation of GPCRs usually 
results in phosphorylation of residues in the intracellular C-terminus, which then interact with 
β-arrestin64.  This interaction induces receptor endocytosis, which terminates receptor 
signalling and results in desensitisation of the receptor to the peptide.  The GnRH1 receptor 
does not undergo agonist-induced phosphorylation or couple to β-arrestin and is therefore 
slowly internalised64.  In contrast, the GnRH2 receptor, which is found in other vertebrates, 
retains the C-terminus and stimulation induces phosphorylation of C-terminus residues, β-
arrestin binding, receptor internalisation and rapid receptor desensitisation.  
How important is biased agonism in drug discovery?  This dichotomy outlined for the 
GnRH receptors suggests that biasing compounds away from β-arrestin recruitment and 
receptor internalisation will reduce desensitisation, which limits drug efficacy.  Bias may have 
additional clinically important consequences. For example, β-arrestin-mediated respiratory 
depression is an adverse consequence of treatment with MOR agonists, which could 
potentially be reduced with biased agonists65. Stretch induced-myopathy in the heart occurs 
as a consequence of the apelin receptor acting as a mechanosensor in the absence of 
endogenous apelin66 that is down regulated in disease.  Replacing the lost apelin with a 




Biased signalling could herald a new, more specific pharmacological strategy for 
GPCR agonists, some examples of which are described in the following sections. However, 
the vast majority of existing examples of biased signalling have been defined using relatively 
simple in vitro cellular outputs.  Predicting clinical benefit will require an understanding of the 
relevant cellular mechanisms that contribute to disease and identification of biased ligands 
from appropriate in vitro cell signalling assays. Many receptors, including those activated by 
GnRH67, opioids68,69, chemokines70, neuropeptide S71, proteinases72 or parathyroid 
hormone73, also exhibit bias but are not discussed in these sections.  
 
Angiotensin II and AT1 receptor.  Biased peptide agonists that target the angiotensin (AT1) 
receptor are the most extensively studied of the peripheral GPCR targets.  This peptide–
receptor pair is important in regulating blood pressure and the AT1 receptor is targeted by 
the ‘sartan’ class of small molecule antagonists, which are used as antihypertensive agents.  
Pioneering studies revealed a synthetic angiotensin II analogue, SII, that bound with 
high affinity, was able to internalise AT1 receptor (presumably by β-arrestin recruitment, but 
this was not measured) and activate the β-arrestin effector mitogen-activated protein kinase 
(MAPK), but did not induce the G protein-mediated production of inositol triphosphate (IP3)74. 
More potent compounds that stimulated β-arrestin-mediated signalling but competitively 
antagonized G protein coupling were subsequently developed, including TRV027 (Sar-Arg-
Val-Tyr-Ile-His-Pro-D-Ala-OH; Table 3).  In rats, TRV027 antagonised AT1 receptor-
mediated G protein signalling and reduced mean arterial pressure, similar to the 
antihypertensive agent losartan.  Crucially, it had the opposite effect to losartan on cardiac 
contractility: TRV027 induced the β-arrestin-mediated activation of kinase pathways and 
increased endothelial nitric-oxide synthase phosphorylation75, with a resulting increase in 
cardiac contractility. This pharmacological profile of an antihypertensive action combined 
with an increase in cardiac output was demonstrated to be beneficial in a dog model of heart 
failure in which TRV027, when co-administered with the commonly used loop diuretic 
furosemide, was shown to preserve furosemide-mediated natriuresis and diuresis76. 
This molecule was then evaluated in patients with acute heart failure with the 
objective of reducing afterload [G] while increasing cardiac performance and maintaining 
stroke volume77.  In individuals with elevated plasma renin levels (indicative of acute heart 
failure), a short, reversible and modest (5 mm Hg) reduction in blood pressure was reported, 
but no change was observed in volunteers with normal renin levels78.  However, no benefits 
were observed on top of standard of care drugs through a 30-day follow-up in a Phase 2B 
randomised, double-blind clinical trial79.  The reasons for this lack of efficay are unclear.  
Insufficient target engagement seems unlikely, as peak plasma concentration (Cmax) at the 
highest dose was ~580 nM which, combined with low plasma binding and high affinity (16 
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nM), would be expected to result in significant receptor occupancy78. Signalling pathways 
may be subtly altered in conditions such as heart failure, which could affect drug efficacy.  
Angiotensin II, SII and TRV027 have distinct downstream phosphorylation events and gene 
expression profiles80, which emphasises the need for comprehensive analyses of signalling 
pathways for biased peptide ligands, some of which are being evaluated for clinical use. 
Peptides have also been developed as tool compounds where the bias is reversed 
compared to TRV027 and presumed, therefore, to be deleterious that should allow further 
insights into this signalling pathway. 
 
The apelin receptor. The apelin system physiologically antagonises angiotensin-II 
signalling.  Although it is not currently targeted by any approved drug, this Class A GPCR 
and its ligands, apelin and Elabela (also called apelin receptor early endogenous ligand or 
Toddler), may have a role in the physiological regulation of the cardiovascular system.  
Dysregulation of the apelin system and loss of endogenous peptides are proposed to 
contribute to a number of conditions, such as pulmonary arterial hypertension81–83 and heart 
failure84,85, indicating potential for more precise targeting of apelin signalling pathways using 
biased ligands. Specifically, a G protein biased agonist, if used to replace the missing ligand, 
would show reduced propensity to desensitise the apelin receptor with repeated use. 
Interestingly, mice lacking the apelin receptor were protected from cardiac hypertrophy and 
heart failure associated with chronic pressure overload, whereas mice lacking apelin itself 
were not66. In the heart, apelin normally stimulates Gαi -mediated protective responses.  
However, the cardiac apelin receptor, in the absence of apelin, acts, via β-arrestin pathways, 
as a mechano-sensor to stretch; cardiomyocytes from apelin receptor knockout mice have a 
reduced hypertrophic stretch response66.  Therefore, apelin receptor ligands that are G 
protein-biased or that preferentially block β-arrestin signalling may be beneficial in patients 
with heart failure.  
Preproapelin is a 77 amino acid peptide that is predicted to be cleaved to biologically 
active peptides including apelin-36 (corresponding to amino acids 42-77), apelin-17, apelin-
13 (corresponding to amino acids 65-77) and a pyroglutamate modified form, [Pyr1]apelin-
13.  In human cardiovascular tissues in vitro, apelin-13, [Pyr1]apelin-13 (which was identified 
as the predominant isoform) and apelin-36 were found to be equipotent as vasodilators and 
inotropes 86; however, apelin-13 and apelin-36 elicited different patterns of receptor 
internalisation in cell based assays  87,88.  These data suggest that putative endogenous 
apelin isoforms may demonstrate unique signalling profiles in vivo. .Whether this might have 
physiological or pathophysiological consequences is not yet known.  However, specific 
pathway bias has been described in vitro: for example, in cAMP and β-arrestin assays, 
16 
 
compared to [Pyr1]apelin-13, the N-terminally extended apelin-17 demonstrated ~70 fold 
bias towards β-arrestin89. Modified peptides based on the apelin sequence also demonstrate 
pathway bias.  Compared to apelin-17, a truncated apelin-17 that lacks the C-terminal 
phenylalanine (Lys16Pro), or versions of apelin-17 and [Pyr1]apelin-13 in which the C-
terminal phenylalanine is replaced by an alanine (Lys17Ala and pGlu13Ala, respectively), 
retained similar binding affinity and potency in inhibiting cAMP but did not induce receptor 
internalisation90.  Indeed, interactions between the C-terminal phenylalanine and residues in 
an aromatic pocket (Phe255 and Trp259 in the rat apelin receptor) are required for apelin-
mediated internalisation91. In terms of downstream signalling events, apelin-17 stimulates 
extra-cellular signal-regulated kinase 1/2 (ERK1/2) phosphorylation in both a Gαi- and β-
arrestin-dependent manner, whereas the action of Lys16Pro was G protein-dependent but β-
arrestin-independent92.  The highly conserved Ser348 in the C-terminus of the apelin 
receptor is critical for interaction with G protein-coupled receptor kinase (GRK), and β-
arrestin-mediated signalling, but replacing Ser348 with Ala did not alter cell surface 
expression of the receptor, binding of apelin ligands or activation of Gαi or Gq pathways93.  
The SAR of biased signalling at the apelin receptor has been assessed with a novel 
series of cyclic peptides based on the apelin-13 structure94.  The main conclusion was that, 
consistent with data for linear peptides, the C-terminal amino acid is important for receptor 
binding, β-arrestin recruitment and receptor internalisation.  In addition, the [Pyr1]apelin-13 
sequence incorporates an N-terminal RPRL motif that is absolutely necessary for receptor 
binding. Earlier SAR studies demonstrated that His7 and Met11 substitutions did not affect 
binding or function of the ligand95.  From these SAR studies it is apparent that modified 
peptides can be designed that may show G protein or β-arrestin signalling bias and this is 
exemplified by the macrocyclic peptide MM0796.  MM07 induced vasodilatation and 
increased cardiac output in rats and in human volunteers, which may be desirable in the 
clinical setting, and, importantly, the receptor was not desensitised on repeated application.  
This peptide has subsequently been shown to have efficacy in a rat model of pulmonary 
arterial hypertension97.  Further modification of MM07 or similarly G protein biased peptides, 
as described above for GLP-1, may result in a peptide with improved plasma half-life to take 
forward to proof of principle clinical studies. 
 
As mentioned above, ghrelin is a gut hormone with a role in hunger signalling which has 
made the ghrelin receptor a potential target for anti-obesity drugs.  However, the 
physiological actions of ghrelin are diverse, including effects on gastric motility, growth 
hormone release, reward behaviour and mood.  Therefore, drugs that mimic or block ghrelin 
may have a number of therapeutic uses but the impetus for developing such agents is 
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hampered by the potential for undesirable on-target side effects.  The discovery of 
compounds that can distinguish between ghrelin responses now suggests that it may be 
possible to develop biased ligands that, for example, selectively reduce body weight.  
Modification of the ghrelin inverse agonist, [D-Arg1,D-Phe5,D-Trp7,9,Leu11]substance P, 
generated compounds containing an N-terminal D-Trp-Phe-D-Trp (wFw) motif with differing 
C-terminal peptide-mimetic spacers98. One of these, wFw-isonipecotic acid, was the first 
ghrelin receptor biased agonist as, unlike known ghrelin mimetics, it did not signal through 
the serum-response element (SRE) pathways (presumably downstream of Gα12/13) but did 
activate the Gαq and ERK1/2 pathways.  A likely explanation was revealed by mutagenesis 
and modelling studies: wFw-isonipecotic acid does not interact with receptor residues that 
are important for the binding and function of ghrelin or other ghrelin mimetics98.  wFw-
isonipecotic acid did not stimulate feeding in rats, which may reflect the relative importance 
of SRE pathways for this function.  If confirmed, these data imply that biased ghrelin ligands 
could be designed that distinguish its effects on growth hormone release from effects on 
food intake99.  For another ghrelin-targeted peptide, Ulimorelin (Table 3), the prokinetic effect  
on gut motility was sustained, unlike the tachyphylaxis [G] seen with other ghrelin agonists. 
Perhaps Ulimorelin does not activate β-arrestin signalling, which would limit receptor 
desensitisation with continued use. Additionally, Ulimorelin mimics the orexigenic and gut 
motility effects of ghrelin, but is not a growth hormone secretagogue.  Whether this unique 
pharmacology is explained by pathway bias is unclear.  Unfortunately, despite Ulimorelin's 
apparent advantages over other ghrelin mimetics, a Phase 3 trial in postoperative ileus was 
discontinued owing to lack of efficacy over. 
 
The ghrelin receptor exhibits high constitutive activity, independent of the cellular 
environment100, that is abolished in a naturally occurring human mutant receptor 
(Ala204Glu)101 that is associated with short stature.  This mutation increases the probability 
that the C-terminal section of extra-cellular loop (ECL) 2 will form an extended α-helix, 
thereby constraining this part of the protein and resulting in loss of constitutive activity101.  
Additionally, whereas ghrelin-stimulated Gq and Gα12/13 signalling were essentially 
unaffected by the mutation, β-arrestin responses were substantially reduced, indicating that 
ECL2 is also important for determining ligand bias.  A role for constitutive receptor activity in 
fasting-induced hyperphagia in mice102 has been proposed. Biased signalling at the ghrelin 





GLP-1 receptors. Class B receptors are also tractable to ligand bias.  Insulin secretion and 
regulation of blood glucose in response to GLP-1 may result from receptor engagement with 
a number of different G proteins and several signalling pathways.  Pathway preference may 
be determined by the agonist and/or the cell type.  Endogenous peptides derived from the 
proglucagon peptide include full-length (GLP-11-36, GLP-11-37) and truncated (GLP-17-36, GLP-
17–37; the mature isoforms) GLP-1, each of which can each also exist in an amidated form, 
as well as oxyntomodulin. The effects of the endogenous peptide agonists, as well as the 
clinically used peptide mimetic Exenatide, have been compared in physiologically relevant 
assays that measure cAMP, Ca2+ mobilization, and ERK1/2 phosphorylation. Using GLP-11-
37 amide as the reference ligand, the shorter GLP-1 isoforms and Exenatide had a similar 
pathway activation profile whereas the longer GLP-1 isoforms and oxyntomodulin exhibited 
some pathway bias104.   Subsequently, from a peptide library screen  an N-terminally 
modified version of Exenatide, Exendin-P5, was identified.  P5 was shown to be G protein-
biased, lacking β-arrestin activity and was more effective than Exenatide in a chronic mouse 
model of T2D105 suggesting that G protein-biased ligands may be advantageous in this 
condition. 
A novel strategy to generate biased versions of GLP-1 involves replacement of 
particular α-amino acids in the peptide backbone with β residues, or with non-proteinogenic 
[G] α-amino acids106,107.  The resulting α–β peptides are resistant to degradation by 
endogenous peptidases.  For example, α-aminoisobutyric acid, a strong helix inducer that 
occurs rarely in nature, protects the N-terminus from degradation by DPP4 and neprilysin.  
Thioamidation limits degradation and thioamidated GLP-1 analogues have an in vitro half-life 
of many hours compared to two minutes for the native peptide108.  Thioamides do not have 
appreciable β-arrestin agonist activity and are therefore also G protein biased.  An 
alternative, but challenging, strategy may be to develop allosteric modulators that affect both 
endogenous peptide binding kinetics and signalling bias109. 
 
Calcitonin receptors.  Experiments using the calcitonin (CT) receptor were some of the first 
to crystallise the understanding that differences in relative agonist potencies in different 
tissues did not necessarily mean that these tissues expressed different receptor subtypes110.  
Both human and salmon calcitonin have FDA approval for treatment of Paget’s disease 
(Table 1 and Table 2).  Interestingly, they exhibit distinct binding kinetics, affinity and 
functional efficacy in different G protein pathways, implying that they stabilise different active 
conformations of the CT receptor111,112. The response to activation of the human receptor is 
complicated by the existence of two major splice variants that exhibit tissue specific 
expression patterns and couple to different signalling pathways113.  The predominant human 
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receptor isoform, CT(a) receptor, lacks a 16 amino acid insert in the first ECL that is present 
in the less abundant CT(b) receptor isoform114.  Both variants bind calcitonin peptides with 
comparable affinity, however, the CT(b) receptor is not internalised well and preferentially 
activates GS over Gq relative to CT(a) receptor115.  Mutational data116 mapped with molecular 
dynamic simulations highlighted that ECL2 was important in conformational propagation 
linked to the Gαs–cAMP pathway, which was distinct to the ligand-specific and pathway-
specific effects propagated by ECL3.  These observations highlighted differences in the 
mechanism of ligand interaction and receptor activation of the CT receptor compared to 
another class B receptor, GLP-1116. 
 
Oxytocin receptors.  Atosiban, described as an oxytocin receptor antagonist, is used 
clinically to prevent preterm labour by blocking the Gq-linked increase in intracellular Ca2+ 
that normally promotes uterine contractility.  However, Atosiban is more correctly identified 
as a biased ligand as it  promotes coupling of the oxytocin receptor to Gαi (which is linked, 
via MAPK, to inhibition of cell proliferation) in addition to antagonising Gαq signalling117.  This 
is of interest because oxytocin receptors are overexpressed in several cancers and therefore 
Atosiban could be repurposed as a chemotherapy.  Interestingly, whilst Atosiban can 
activate or inhibit pathways downstream of different Gα proteins, it has little effect on β-
arrestin signalling: receptor internalisation was markedly attenuated following exposure to 
Atosiban, whereas these receptors are rapidly and profoundly lost in response to oxytocin117. 
Furthermore, oxytocin-triggered IP3 accumulation was competitively blocked by pre-
exposure to Atosiban117.  It has subsequently been confirmed that Atosiban does not recruit 
β-arrestin to the oxytocin receptor and shows selectivity for Gαi3 over other Gi isoforms118. 
 
Insights from structural studies 
Experimental X-ray crystallography or cryo-EM structures have been reported for the 7-
transmembrane domains of 62 GPCRs, covering 212 distinct GPCR–ligand complexes and 
200 unique ligands119,120. Of these GPCRs with solved structures, 27 of them bind peptides 
or proteins, with 65 solved unique receptor–ligand complexes115,116,121-157. Twenty two of the 
experimentally determined GPCR structures (10%) so far (see the GPCR database in 
Related links), contain a peptide ligand, covering Class A and B GPCRs (Figures 3 and 4, 
Supplementary Table 1).  The peptide-bound structures of these receptors provide structural 
templates and detailed insights into the structural determinants of ligand binding and 
functional activity (Box 3, Supplementary Text and Supplementary Table 1). About half of the 
clinically relevant peptides reported in Tables 1, 2 and 4 have been structurally modelled 
based on homologous peptides and/or receptors.  These peptides serve as potential 
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templates for the structure-based optimisation and design of novel GPCR peptide 
therapeutics.   
Peptide ligands bind to GPCRs with numerous different binding modes, reflecting the 
diverse chemical structures and properties of both ligands and receptor binding sites.  Class 
A GPCR peptide ligands generally bind to ECL2,  and  polar or ionic interaction site at the 
top of ECL3 (the portion of the protein between transmembrane region 6 (TM6) and TM7) 
and bind differentially located and shaped lipophilic regions deeper in the receptor pocket.  
Most Class B GPCR ligands are helical, and the helical ligands have a lipophilic interaction 
with a site in the region between TM1, TM2 and TM7 that is less accessible in Class A 
GPCRs, and some of the Class B ligand specificity is determined by polar interaction 
networks that can form with different relative orientations of the extracellular N-terminal 
domains (ECDs) and the transmembrane domains149.  
Class B GPCRs contain an ECD of 120–160 residues and a transmembrane domain 
of 310–420 residues.  In addition to the transmembrane-domain-only and full-length 
structures of class B GPCRs that have been described, several structures of isolated class B 
GPCR ECDs have been solved149 (Supplementary Table 1).  These ECD–peptide 
complexes have conserved hydrophobic interactions between conserved lipophilic residues 
in the C-terminal part of the ligand and hydrophobic interaction sites in the ECD of the 
corresponding receptor.  
Considerable progress has been made in elucidating the three dimensional 
structures of key regions for peptide recognition and selectivity by GPCRs. Methodological 
and technical improvements to cryo-electron microscopy are expanding the role this 
technique occupies alongside X-ray crystallography in solving GPCR structures. Emerging 
information on different activation states and structural features responsible for activation or 
inhibition are being exploited to guide drug discovery. This is particularly important for Class 
B, where all endogenous ligands are peptides and there is potential to discovery new 
compounds based on exploiting allosteric binding sites revealed by structural studies. Future 
studies will help to unravel the importance of receptor dimerization and the rational, rather 
than empirical, design of biased peptide ligands, as our knowledge expands of key residues 
involved in the kinetics and dynamics of signalling processes such as β-arrestin. 
 
Perspectives and conclusions 
Nearly all peptide drugs approved for clinical use to date function as full agonists.  This 
probably reflects the predominant strategy for the discovery of clinical candidates, which is 
based on structural modifications to naturally occurring peptide sequences, rather than high-
throughput screens against target receptors, which are often used to identify small 
molecules leads. This may, however, be set to change. The number of deduced structures of 
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GPCRs that bind peptides is rapidly increasing using crystallography (Supplementary Table 
1), which will enable the rational structure-guided design of peptides. This approach will 
expand further because of cryoEM, from which, crucially, structures can be determined from 
GPCRs bound to an agonist in an active state, as has been successfully done for Class B 
receptors133,137,140. Indeed, peptide allosteric modulators have been proposed for the 
urotensin II receptor that block urotensin II-mediated contraction of aortic rings, but have no 
effect on the activity of the second endogenous agonist that binds the receptor, urotensin II-
related peptide158. Structure-guided design may therefore enable peptides drugs to 
selectively distinguish between and modulate the action of two endogenous peptides that act 
at the same receptor, one of which causes a detrimental pathophysiological action, perhaps 
owing to differences in spatial or temporal signalling.  Strategies such as screening phage 
display peptides have also been effective in discovering novel peptide ligands; for example, 
antagonists of the Class B VIP2 receptor that have nanomolar affinity were identified using 
this approach159. 
How do we use this information to synthesise a better peptide drug? This Review 
highlights one major trend over the last two decades: the successful exploitation of unnatural 
amino acids and chemical modifications to manipulate physicochemical properties, 
principally to improve pharmacokinetics but also, to a lesser extent, pharmacodynamics. 
Another, earlier stage trend stems from the discovery of peptides that can be biased towards 
G protein-dependent or G protein-independent β-arrestin-mediated pathways.  
Biased ligands have enormous potential to selectively activate pathways that 
produce beneficial clinical effects while reducing signalling via pathways that may cause 
unwanted on-target side effects.  Biased peptide agonists have been identified for a number 
of receptor families and clinical proof of concept studies are emerging94.  As proof of 
principle, but subsequent to clinical approval, the OT receptor antagonist Atosiban was 
identified as biased as it does not activate β-arrestin, thereby reducing internalisation, which 
is an important aspect of its mechanism of action118. 
Particularly compelling evidence for the need for biased agonists has emerged from 
studies of the MC4 receptor.  Remarkably, gain of function mutations identified in humans 
that were associated with reduced body mass index and protection from T2D and coronary 
artery disease were biased towards the β-arrestin pathway.  This suggests that β-arrestin 
biased MC4 agonists that act at the native receptor may be a new strategy for the treatment 
of obesity160. Individuals from the 1000 Genomes Project had, on average, sixty eight 
missense variations that occurred within the coding regions of one-third of the GPCR drug 
targets; only eight of these variants had previously known clinical associations with altered 
drug response161. In data from ~68,000 individuals in the Exome Aggregation Consortium 
(EXAC), variants were found in the drug binding sites of 108 GPCRs162.  Interestingly, 
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variants of MOR and CCKA, which binds cholecystokinin, were shown experimentally to have 
an altered drug response.  These results suggest that mining databases such as that from 
100,000 Genomes,163 in which disease phenotypes are linked with whole genome 
sequencing and patients can be recalled, will yield additional variants that experimentally 
lead to a loss or gain of function that can be used to identify new GPCR targets for novel 
treatments. 
Dual agonist peptides that activate two different GPCRs are also emerging. The 
focus to date has been on combinations that target GLP-1 receptor with either the 
glucagon164 or GIP receptors165,166.  Interestingly, a compound that binds to all three 
receptors is in Phase 1166.  In a Phase 2 trial, a molecule that contained both GLP-1 and GIP 
sequences significantly improved glycaemic control and reduced body weight in patients with 
T2D167.  The rationale was that the two peptides account for most of the effects of incretins 
[G].  However both are degraded by DPP4.  Therefore, designing a peptide that contains 
both peptide sequences but lacks DPP4 cleavage sites to enhance plasma half-life could 
mimic the beneficial effects of incretins.  Clearly a single molecule is an attractive strategy 
for synergy and patient compliance, but empirical determination of the optimum relative 
balance between the potency of the two agonistic effects of this single molecule is 
challenging.  Stapled peptides that constrain α-helices to lock a peptide in a particular (often 
active) confirmation are being explored, for example, as modified orexin168 and 
oxyntomodulin169 ligands.  Similarly, pepducins, which are derived from short sequences of 
intracellular loops of GPCRs and lipidated to penetrate cells so they can access allosteric 
sites and stabilise GPCR confirmations are being developed170 and some are being tested in 
experimental medicine studies in the clinic171. 
In pharmacokinetics, modifications to dramatically increase plasma-half life from a 
few minutes to days have been the most revolutionary, and a range of strategies effectively 
reduce metabolism and/or renal excretion. Sustained release formulations are another key 
development.  Theoretically, these innovations can be applied to virtually any peptide. 
Promising experimental or early stage trials include genetically engineered exendin‐4 
linked to a single domain albumin binding antibody (AlbudAb), which prolonged plasma half-
life to 6-10 days while maintaining agonist activity (measured as the expected reduced 
postprandial glucose and insulin levels, and delayed gastric emptying)172.  An alternative 
strategy has been employed to chemically link an apelin peptide analogue to a single 
domain antibody173.  The advantage of using a chemical link is that non-genetically encoded 
amino acids can be introduced, so this agonist has high affinity for the apelin receptor but is 
also resistant to peptidase-mediated degradation.  Genetically engineered peptide-AlbudAb 
conjugates, for example, cannot be made resistant to peptidases in the same way. 
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Nanotechnology strategies have been applied to induce reversible peptide self-
assembly to prolong the bioactivity of a peptide in vivo.  As proof of concept, Ouberai et al.174 
demonstrated that oxyntomodulin self-assembled into a stable nanofibril formulation, which 
subsequently dissociated in vivo to release active peptide, thereby prolonging detectable 
activity in the plasma from 4 hr to 5 days.  Oral (albeit with low bioavailability) and nasal 
delivery are being used in the clinic to avoid daily injections and these strategies will be 
increasingly explored.  The challenge of engineering peptides that cross the blood–brain 
barrier remains, and many GPCRs with peptide ligands reside in the brain.  Linking GPCR-
targeting peptides to a brain-penetrant peptide to transport compounds across the blood–
brain barrier is being investigated experimentally.  Finally, there is an expanding number of 
potential new GPCR targets as orphan GPCRs continue to be paired with peptide ligands175. 
It is not yet clear where the balance lies in the cost of developing a clinical candidate 
based on a peptide versus a small molecule.  However, the development of new GPCR 
peptide drugs continues on an upward trajectory, with seven approved by the FDA in 2017-
2019 and over ten in the pipeline in Phase 2 and 3, which is mirrored by the rise in the 
estimated global value of US$25.4 billion.  
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Glossary terms  
 
Cryo-electron microscopy 
Electron microscopy technique that allows near atomic resolution of biomolecules such as 
GPCRs in samples cooled to low temperatures and embedded in an environment of vitreous 
water, avoiding the need for crystallization required for X-ray crystallography. 
 
Flip-flop kinetics 
A property of compounds that are administered by subcutaneous injection and slowly 
absorbed, resulting in fairly continuous release of the compound into the blood.  
Afterload 
The pressure against which the heart must work to eject blood. 
Tachyphylaxis 
The rapidly diminishing response to repeated doses of a therapeutic agent.  
Non-proteinogenic 
Not naturally encoded in any known organism. 
Incretins 
Metabolic hormones, induced upon eating, that decrease blood glucose by stimulating 
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Many of the first peptide drugs were entirely comprised of proteinogenic (naturally occurring) 
amino acids.  These drugs had limited stability in the body owing to rapid enzymatic 
degradation by peptidases and renal elimination.  They required administration 
subcutaneously or intravenously because they had little or no oral bioavailablity8.  Next-
generation peptide drugs often incorporated unnatural amino acids residues such as D-amino 
acids, N-methyl amino acids or residues with unnatural side chains.  Chemical modifications 
— monomeric groups other than amino acids that are added to peptides during synthesis — 
also became more relevant. These modifications include N-terminal modifications, C-terminal 
caps, fatty acids and polyethylene glycol (PEG) groups.  Of the 49 approved peptide drugs for 
GPCRs, 22 comprise all natural amino acids, three contain at least one unnatural amino acid, 
three have at least one chemical modification and 21 have both chemical modifications and 
unnatural amino acids (see Figure). 
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Cosyntropin (an adrenocorticotropic hormone analogue) was the first peptide targeting 
a GPCR to be approved for therapeutic use, in 1967, and consisted of only natural amino 
acids (including pyroglutamic acid, which is produced in the human body).  Amongst the next 
eleven peptides for GPCRs that were approved over the next 20 years (until 1987), only one 
(Pentagastrin) contained an unnatural amino acid (β-alanine, butyloxycarbonyl-protected), 
and one, Leuprolide, had a C-terminal N-ethyl cap and an unnatural D-Leu residue. Since 
then, the ratio of approved peptide drugs that contain an unnatural residue or chemical 
modification to all-natural amino acid peptides has continued to rise. From 2010–2019, 16 new 
peptide drugs targeting GPCRs were approved, only five of which comprised exclusively 
natural amino acids. 
The addition of unnatural residues or chemical modifications is generally used to alter 
properties such as efficacy, potency, sub-type selectivity, pharmacodynamics or 
pharmacokinetics176.  The first of the gonadotrophin-releasing hormone (GnRH) receptor-
targeting peptides that was approved for hormonal disorders (such as breast, ovarian, 
endometrial or prostate carcinoma) was a natural peptide (Gonadorelin), but subsequently 
approved drugs targeting the same receptor incorporated unnatural residues that changed the 
route of administration, and improved potency and stability177.  
Octreotide was the first somatostatin receptor agonist and was approved in 1987 for 
acromegaly and gastroentero-pancreatic tumours. Octreotide has an unnatural D-Trp residue 
and a modified Thr residue, which enable the eight-residue Octreotide to function as an 
effective mimetic of the endogenous peptide, somatostatin (which has 14 residues)178.  Further 
research resulted in the approval of Lanreotide (in 1994), which incorporates an unnatural D-
2-Naphthylalanine residue, and has superior clinical efficacy179. Pasireotide (approved in 
2005) is a heavily engineered cyclic peptide comprised of six amino acids, five of which are 
unnatural. This enables both a reduction in size of Pasireotide versus Octreotide, and 
increased in vivo stability (half- life = 12 hours versus 1.67 hours)180. 
Glucagon-like peptide 1 (GLP-1) receptor agonists are important agents for the 
treatment of type 2 diabetes (T2D) and other metabolic disorders.  The first approved GLP-1 
receptor agonist for T2D was Exenatide, which was approved in 2005, and since then six more 
agents have been brought to market for the same indication181. How the structure of these 
peptides affects their pharmacology and effectiveness as drugs is discussed in detail in the 
text. Peptides linked to larger molecules, including Albiglutide (GLP-1 dimer fused to human 
albumin) and Dulaglutide (GLP-1 analogue covalently linked to a human IgG4-Fc heavy chain 






Box 2 Quantifying ligand bias  
 
The hypothesis that agonist-specific GPCR active states result in agonist-specific activation 
of signalling pathways was proposed almost two decades ago110 in response to data that did 
not fit the accepted two-state receptor models.  The concept that compounds with affinity for 
the same receptor can induce ligand-specific GPCR conformations, and each elicit a 
particular pattern of downstream activation, is now well established182.  Early evidence for 
biased agonists includes the observation that the rank order of relative potencies and/or 
maximal responses for ligands could be different for different signalling pathways regulated 
by a unique receptor110.  In the extreme, compounds might activate one pathway and inhibit 
another pathway, both of which are activated by the same receptor182, 183.  This simple 
measure of bias has been superseded by more sophisticated analyses that compare test 
compounds to a reference ligand and allow for assay differences in receptor density and 
coupling efficiency.  One such analysis184 uses a reference ligand, which can be any 
compound, although the endogenous agonist for the target receptor may be most 
appropriate (as used in this Review), and is used to distinguish system bias from ligand bias.  
Biased ligands, which may include the reference compound, stabilise a particular 
conformation of the receptor that preferentially interacts with one or a subset of signalling 
pathways.  Compounds might be compared in many assays to determine an exhaustive 
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signalling profile but, in practice, clinically relevant signalling pathways are examined to 
define lead compounds with the desired pharmacological signature. Confounding bias from 
the assay, system and kinetics should be carefully avoided185, 186. 
Biased agonists and antagonists. Compared to the reference ligand (blue) a 
biased compound may have similar potency in pathway A but demonstrate lower potency 
(green), or no agonist activity (red) in pathway B. Whether a biased agonist with normal 
activity in pathway A but no effect on pathway B behaves as an antagonist of the 
endogenous agonist is not usually reported, but could be relevant.  If the biased agonist is 
being used to replace a missing endogenous peptide and there is benefit in activating some 
downstream signalling pathways but not others (for example, activating G protein-dependent 
pathways but not β-arrestin recruitment, which should limit receptor internalisation and 
desensitisation) then it is probably not critical whether the biased compound has reduced or 
no potency in this second pathway.  However, in conditions in which there is overactivation 
of a receptor system, a biased ligand with no effect on pathway B would specifically 
antagonise the effects of the endogenous peptide on this pathway.  Other biased ligands 
may antagonise all pathways but show quantitatively greater functional affinities for one 




























Biophysical, pharmacological, site-directed mutagenesis and biomolecular simulation 
studies, combined with comparative analysis of different conformational states of recently 
released antagonist-bound and agonist-bound peptide GPCR structures (Supplementary 
Table 1, Figure 3), have provided insights into structural interaction networks that determine 
biased signalling for several peptide-binding GPCRs, including those in class A (such as the 
receptors for angiotensin (AT1 and AT2)122 or apelin121) and class B (such as the receptors 
for calcitonin116 or glucagon-like peptide 1 (GLP-1)187, 188). These structural determinants of 
biased signalling connect ligand binding sites, transmission switches in the core of the 
receptor, and intracellular interaction networks linked to G-protein and β-arrestin coupling 
binding sites189, 190. 
AT1 receptor.  Several residues in the AT1 receptor are involved in signalling pathway 
bias191, including Y2927.43 (Ballesteros Weinstein GPCR numbering) in the ligand binding 
site, D742x50 in the allosteric sodium binding site192, and N2987.49 and Y3027.53 in the NPXXY 
tyrosine switch region189,190 . Double electron-electron resonance (DEER) spectroscopic 
data193 mapped on the peptide-bound, nanobody-stabilised active AT1 structure122 showed 
that: Gq-biased peptides stabilize a receptor conformation in which the first transmembrane 
domain (TM1) is located far apart from TM6 and intracellular loop 2 (ICL2); β-arrestin-biased 
ligands stabilise a conformation in which TM1 and ICL2 are in closer proximity and TM1 is 
far apart from TM6; and inverse agonists stabilize a receptor population in which TM1 and 
TM6 are relatively close to each other and ICL2 is far apart from TM7, consistent with 
conformational differences between active122 and inactive 194,195 AT1 receptor structures. 
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Apelin receptor. A cluster of residues (I1093x32, F1103x33, M1133x36) that forms an interaction 
network with Phe13 of apelin plays an important role in biased signalling196. This cluster is 
connected to the transmission switch region between A1173x40, P2135x50, F2145.51, F2576.44 
and K2616X48 that are part of a hydrophobic hindering mechanism that locks class A GPCRs 
in the inactive state189,190. 
Calcitonin (CT) receptor. Residues in the top of TM4 and extracellular loop 2 (ECL2, 
including I2794x62, T2804x63, R2814x64, V2834x64, N28645x46, S29245x53, E29445x55 and H29645x57) 
are important in conformational propagation linked to the Gαs–cAMP pathway. This network 
is specific to the ligand and the pathway. Effects are propagated by the top of TM6/TM7/EL3, 
and the top of TM7116, including F3566.53, V3586.55, M3677x33, L3687x34, G3697x35, Y3727x38, 
M3767x42. 
GLP-1 receptor. Several residues in ECL1, ECL2 and ECL3, and in the top of TM3 (R2273x30), 
TM4 (K2884x64) and TM5 (R3105.40) that line the orthosteric hormone binding site play ligand-
specific roles in biased signalling 187, 197. Several additional regions connecting the peptide 
ligand binding site and the intracellular G-protein and β-arrestin binding regions have been 
identified in the GLP-1 receptor188, consistent with conformational differences between active 
and inactive GLP-1 receptor structures133,136,137,149,198. 
Residues involved in biased signalling in AT1 receptor, and apelin, CT and GLP-1 receptors 
in mutagenesis studies are highlighted and coloured red on the corresponding receptor 
structures in the figure: aligned Ang II [Sar1, Ile8] bound to AT1 receptor (Research 
Collaboratory for Structural Bioinformatics (RCSB) protein data bank (PDB) ID: 6DO1)122; 
AMG3054 bound to apelin receptor  (PDB ID: 5VBL)121; calcitonin bound to CT receptor (PDB 


















Figure 1 | Overview of GPCR-targeted peptide drugs. The number of peptide drugs that 
are approved, in Phase 3 or in Phase 2 clinical trials are shown for  receptors from Class A 


















Figure 2 │ 2D and 3D diagrams of peptides targeting receptors for GnRH1 or GLP-1 
and/or GLP-2.  Peptides are shown as beads based on the three-dimensional position of Cα 
atoms of the structural templates of these peptides bound to experimentally determined 7-
transmembrane domain (7TM) structures of associated G protein-coupled receptors 
(GPCRs) (Supplementary Table 1).  The orientations of the 3D peptide bead strings are 
consistent with their binding mode in the GPCR binding site (Figure 4), assuming a view in 
which transmembrane domain 1 (TM1) is on the left, TM5 is on the right, and the extra-
cellular side is facing up. See Supplementary Figure 2 for further structures of peptide drugs 






Figure 3 │ Overview of structure determination for the GPCRs.  Peptide GPCRs for 
which 7-transmembrane domain (7TM) or full-length structures are available in complex with 
peptide ligands (red) or only in complex with non-peptide ligands (turquoise) are 
distinguished from peptide GPCRs for which only extracellular domain (ECD) structures are 
available (green) and non-peptide GPCRs for which 7TM or full-length structures are 
available (blue). For details, see Supplementary table 1.  Related GPCR families — 
adhesion, glutamate, frizzled  and taste (TAS2) are shown for reference.  Receptors are 
classified as orphans when the endogenous ligand(s) is not yet established. The rhodopsin 
family is shown classified into four groups: α-group includes amine,  peptide and 
prostaglandin receptors; the β-group includes only receptors that bind peptides; the γ-group 
contains chemokine receptors, some receptors that bind peptides such as somatostatins, 
galanin, and opioids and receptors that bind other types of ligands; the δ-group includes 







Figure 4 │ X-ray crystallography and cryo-electon microscopy structures of GPCRs. 
The panels summarise structural interactions for aligned binding site residues of class A and 
class B peptide GPCRs forming polar H-bond or ionic interactions (red), or only lipophilic 
interactions (grey) with peptide ligands shown in the individual binding mode figure panels. 
For the Class A GPCRs, the binding sites of AMG3054-bound apelin receptor (protein data 
bank identifier (PDB ID): 5VBL)121, octapeptide Ang II [Sar1, Ile8] partial agonist-bound 
angiotensin AT1 (PDB: 6DO1)122, Complement C5a1 bound to PMX53 (PDB: 6C1Q)124, 
Endothelin-bound ETB (PDB: 5GLH)125, neurotensin-bound NTS1 (PDB: 3ZEV) 125, UR-
MK299-bound neuropeptide NPY1   (PDB: 5ZBQ)141, DAMGO-bound MOR (PDB: 6DDE)128, 
and CCL5-bound CCR5 (PDB: 5UIW)129 are shown. For class B GPCRs, calcitonin gene-
related peptide (CGRP) receptor bound to Gs [Au: Edit ok?] (PDB: 6E3Y)134, NNC-1702-
bound glucagon receptor (GCGR) (PDB: 5YQZ)135, peptide 5-bound (PDB: 5NX2)136 and 
Exendin-P5-bound (PDB: 6B3J)135 GLP-1 receptor, and ePTH-bound parathyroid receptor 
(PTH1) 139 are shown. Views are focused on the 7-transmembrane domain and are 
consistent with the orientations of peptide diagrams shown in Figure 2. The binding pocket 
surfaces (grey mesh) are contoured at 1 kcal/mol using the C3 (carbon sp3) GRID probe199, 
whereas lipophilic areas are defined using the C1= (lipophilic) probe contoured at -2.8 to -3.0 
kcal/mol, customized to GPCR binding sites200. Generic GPCR residue numbers201 are 
provided based on Ballesteros–Weinstein Class A GPCR (apelin receptor, AT1, C5a1, CCR5, 
ETB, MOR, NPY1R)202 and Wootten203 Class B GPCR (CGRP, Glucagon, GLP-1, PTHR1) 
numbering schemes. According to these schemes, the first number (1-7) denotes the 
transmembrane helix, and the following number indicates the residue position relative to the 
most conserved amino-acid in the helix (which is assigned the number 50), considering 








Table 1| Endogenous peptides targeting Class A and B GPCRs that are approved for clinical use 





















AT1 8.8 9.0–9.3 
AT2 10.2a ND 
Melanocortin Diagnosis, adrenal insufficiency 
Cosyntropin 




Testing response of 
anterior pituitary 






Protirelin); 1976 5.3 
TRH1 7.4b 8.5 
TRH2 7.4b ND 
Vasopressin 
and oxytocin Induction of labour 
Oxytocin (Otx; Pitocin; 
Syntocinon); 1980 1–6 
OT 8.2–9.6 7.8–10.4 
V1A 6.9–8.3 8 
V1B 5.7–7.0 6.6–7.6 






OT 7.3–9.3 ND 
V1A 8.5–9.3 9–9.6 
V1B 9.9 8.3–8.7 
V2 7.9–9.1 10.3 
Class B 





AMY1 ND 8.9–11.3 
AMY2 ND 11.4 
AMY3 ND 8.0–10.6 
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CT 9 9.0–11.2 
Glucagon 
Severe hypoglycaemia Glucagon; 1998 8–18 
GLP1R 6.9–7.0 ND 
Glucago
n ND 9.0 






11; rhPTH(1-84)); 2006 90 
PTH1 ND ND 
PTH2 ND ND 
Post-menopausal 
osteoporosis Teriparatide; 2002 5 
PTH1 7.4c ND 
PTH2 7.7-7.8c ND 
 
a pKD (negative logarithm to base 10 of the equilibrium dissociation constant for ligand receptor 
interactions); b Derived from studies of the rat receptor; c pIC50 (negative logarithm to base 10 of the 
concentration of competing agonist or antagonist that inhibits the binding of a radioligand by 50% in 
a competition binding assay). Endogenous peptides approved for clinical use were identified from 
the GuidetoPharmacology database3, which has the most extensive classification. The list was 
compared with the DrugBank database, with further information from RxList, Global Data or relevant 
company websites (See Related links). Pharmacokinetic and pharmacodynamics parameters were 
curated from GuidetoPharmacology3, DrugBank and the original citations.  The peptides identified 
are in use in any geographical region, but largely reflect those used widely in major pharmaceutical 
markets such as North America, Asia and Europe, and our analysis may not have captured peptides 
licensed in just one country. A range of affinities and potencies are given if ranges were reported. 
For peptides with affinities for more than one subtype within the family, all values are shown where 
available. Affinity and potency data are derived from human receptors, except where indicated. 
Plasma half-life calculations are based on intravenous administration, but clinical administration may 
be via other routes, such as intra-muscular or intra-nasal, that may alter these values. Information 
on volume of distribution and percent plasma binding can be found in Supplementary Table 2. 
Human parathyroid hormone (1-84), manufactured as a recombinant form with the full 1-84 amino 
acids was approved for clinical use as Natpara, (ALX1-11, rhPTH1-84) but it is included as shorter 
sequences are also effective in activating target receptors. Teriparatide is a synthetic peptide 
comprising 1-34 of the N-terminal amino acids of human parathyroid hormone. iv, intravenous; ND, 
no data available from online resources; pEC50, the negative logarithm to base 10 of the molar 
concentration of an agonist that produces 50% of the maximal possible effect of that agonist; pKi, 
negative logarithm to base 10 of the concentration of the competing ligand that would occupy 50% 




Table 2 | Modified peptides targeting Class A and B GPCRs that are approved for clinical use 
















Bradykinin Hereditary angioedema 
Icatibanta (D-Arg-
[Hyp3,Thi5,D-Tic7,Oic8]BK; 
HOE140; Firazyr); 2008 
1–2 
1.4b B2 receptor 10.2 8.0–9.4 
Cholecystokini


















Buserelin (HOE 766; HOE 








































471; RU-19847); 1986 




Goserelin (Decapeptide I; 
ICI 118630; Zoladex); 
1989 




Histrelin (Supprelin LA; 
Vantas; ORF 17070; RWJ 
17070); 2004 








43818; TAP-144; Eligard; 
Carcinil; Prostap; 
Lutrate); 1985 


















0.1, 0.75, 3 
GnRH1 
receptor 8.5–8.8 ND 
Prostate 
cancer 
Abarelixa, d (PPI 149; R 
3827; Plenaxis); 2003 317±77 
GnRH1 






(Scenesse); 2014 0.8–1.7 
MC1 receptor 10.0e ND 
MC3 receptor 8.9 ND 
MC4 receptor 8.5–8.8 ND 




Rekynda); 2018 2 
MC1 receptor ND ND 
MC3 receptor ND ND 
MC4 receptor 8.0e ND 






2019 2 κ receptor ND 9.8 
Relaxin Heart failure 
Serelaxin (Reasanz; RLX-
030; recombinant human 
relaxin 2); 2016 





Pasireotide (SOM 230; 
Signifor), 2012 12 
SST1 receptor 8.0e ND 
SST2 receptor 9.0 e ND 
SST3 receptor 8.8 e ND 





Lanreotide depot (DC 13-
116; Somatuline; Ipstyl; 




SST1 receptor 6.7e  ND 
SST2 receptor 8.7–9.6 ND 
SST3 receptor 7.2–8.0 ND 






Longastatin; SMS 201 





SST2 receptor 8.7–9.9  ND 
SST3 receptor 7.4–8.6 ND 




Vapreotide (BMY 41606; 
CCRIS 6495; RC-160; 
Sanvar IR; Vapreotide 
acetate); 2009 
0.5 
SST2 receptor 8.3–10.1 ND 
SST3 receptor 7.4–7.9 ND 







RWJ 22164; d[D-Tyr(Et)2, 
Thr4,Orn8] vasotocin; d 
[D-Tyr(Et)2 Thr4]OVT; 


























OT receptor 6.7–7.6 ND 
V1A receptor 7.0–7.7 ND 
V1B receptor 7.7–8.2 ND 
V2 receptor 7.2–8.6 ND 
Haemostatic 






Lucassin); 2006 0.4–1.1 
V1A receptor ND ND 
V1B receptor ND ND 















1–1.1 b AMY1 receptor 8.7-9.7e 10.0 
Pain caused by 







AMY1 receptor ND 9.4 
AMY2 receptor ND 8.6–8.9 
AMY3 receptor ND 9.1–9.3 






acetate; Geref); 1990 
0.17 








0.43 b GHRH receptor 10.2 ND 
T2DM 
Albiglutide protein, fused 
(GSK-716155; Eperzan; 
Tanzeum); 2014 







120 b GLP-1 receptor ND ND 
T2DM 
Exenatide (Exendin-4, 
AC002993; AC 2993; 
AC2993A; Byetta; 
Bydureon); 2005 
2.4 b GLP-1 receptor  8.7–9.0 9.2e ND 
T2DM Liraglutide (NN-2211; Victoza; Saxenda); 2009 13





3 b GLP-1 receptor  8.9 ND 
T2DM Semaglutide spacer (NN-9535; Ozempic); 2017 168



























72–96 b CaS ND 4.6 
 
a Antagonist; b half-life following subcutaneous injection; c pKD (negative logarithm to base 10 of the 
equilibrium dissociation constant for ligand receptor interactions); d Abarelix was discontinued in 
United States in 2003, owing to allergic reactions, but clinical use has continued in Europe; e pIC50 
(negative logarithm to base 10 of the concentration of competing agonist or antagonist that inhibits 
the binding of a radioligand by 50% in a competition binding assay);  f Lutathera is a radiolabelled 
peptide that exploits radiation to kill tumours; g withdrawn in United States; h Derived from studies 
of the rat receptor; i Dulaglutide contains GLP-1 (amino acids 7-37) with substitutions Ala8Gly, 
Gly22Glu, Arg36Gly, a 16 amino acid linker sequence and a 228 amino acid synthetic human Fc 
fragment (immunoglobulin G4) - two identical peptide chains form a dimer, linked by inter-monomer 
disulphide bonds between Cys55-55 and Cys58-58. All molecules are agonists unless otherwise 
indicated. Compilation of the data used the databases and methods as outlined in Table 1.  The table 
reflects the consensus that synthetic peptides act primarily on a single receptor or family of 
receptors (such as the somatostatin family).  Cyclosporin, which is reported to be an antagonist of 
formylpeptide receptor, has been omitted as it is reported to be nonselective.  The main clinical uses 
in DrugBank, RxList, Electronic Medicines Compendium and Clinical Trials.Gov are listed under 
clinical indication. A range of affinities and potencies are given if ranges were reported. For peptides 
binding to somatostatin receptors, the relative importance of the affinities for the different subtypes 
in the therapeutic action is unclear and all values have been included. Affinity and potency data are 
derived from human receptors, except where indicated. Plasma half-life calculations are based on 
intravenous or subcutaneous administration, but clinical administration may be via other routes, 
such as intra-muscular or intra-nasal, that may alter these values. For example, calcitonin (salmon) 
plasma half-lives are: intra-muscular, 0.96 hr, intra-nasal 0.3-38 hr. Information on volume of 
distribution and percent plasma binding can be found in Supplementary Table 3. iv, intravenous; ND, 
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no data available from online resources; pEC50, the negative logarithm to base 10 of the molar 
concentration of an agonist that produces 50% of the maximal possible effect of that agonist; pKi, 
negative logarithm to base 10 of the concentration of the competing ligand that would occupy 50% 
of receptors as determined in a competition binding assay. 
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Table 3 | Peptides in the pipeline 
Family Receptor Ligand; mechanism of action Clinical indication 
Year of study 
initiation Synonyms 
Ongoing Phase 3 trials, Class A GPCRs 
Chemokine CXCR4 BL-8040; antagonist 
Stem cell mobilisation 
for HSCT for multiple 
myeloma 
2019 None 














Ongoing Phase 3 trials, Class B GPCRs 
Glucagon GLP-2  Glepaglutide; agonist Short bowel syndrome 2019 ZP1848 
Ongoing Phase 2 trials, Class A GPCRs 
Gonadotrophin-
releasing hormone GnRH1  EP-100; agonist
a Ovarian cancer 2017 None 








oxytocin OT  Barusiban; antagonist 
Infertility and IVF 
treatment 2019 None 
Ongoing Phase 2 trials, Class B GPCRs 
Corticotropin-
releasing factor CRF2 RT-400; agonist 
Acute decompensated 




















GLP-2  Apraglutide; agonist Short bowel syndrome 2018 FE203799 
Discontinued during or after Phase 3 trials, Class A GPCRs 

















activated PAR1 Rusalatide; agonist





Oxytocin V1A  Selepressin; agonist Septic shock 2018 None 
Discontinued during or after Phase 3 trials, Class B GPCRs 
Corticotropin-
releasing factor CRF1  Corticorelin; agonist 






















Discontinued during or after Phase 2 trials, Class A 
5-
Hydroxytryptamine 5-HT2A  Nemifitide; antagonist Major depression 2010 NO 
Angiotensin AT1  TRV027; biased ligand Heart failure 2016 TRV120027 
Endothelin ETB  SPI-1620; agonist 
Non small cell lung 






Ghrelin Ghrelin  
GTP-200; agonist Cancer cachexia or anorexia 2007 
Ghrelin; 
GTP 200 
TZP-102; agonist Diabetic gastroparesis 2012 None 


















Y4  TM30339; agonist Obesity 2012 None 




a EP-100 comprises GnRH and CLIP-71 (an 18 amino acid cationic α-helical lytic peptide). b Rusalatide 
comprises 23 amino acids of the receptor binding domain of pro-thrombin. c MAR701 and MAR709 are 
PEGylated compounds. Data classified as in Phase 2 or 3 as of 2019 were retrieved primarily from Global 
Data, ClinicalTrials.gov or relevant company websites (see Related links). Studies can be in any 
geographical region. Trials were considered discontinued if no activity had been recorded in three years 




SST1  Veldoreotide; agonist Acromegaly 2007 COR-005; DG3173 




Discontinued during or after Phase 2 trials, Class B 
Calcitonin CGRP CGRP; agonist 
Myocardial infarction, 
asthma 2007 None 
CT Davalintide; agonist Obesity 2010 AC2307 
Glucagon 
GHRH  AKL-0707; agonist 
Malnutrition associated 






DAC:GRF; agonist Obesity 2006 CJC-1295 
GIP  




























Glymera; agonist T2DM 2016 PB1023 
























Summary of modifications 
Exenatide 2005 53% Twice 
daily 
2.4 39-amino-acid synthetic peptide analogue 
Exendin-4,   a toxin from Gila monster saliva 
Liraglutide 2009 97% Daily 13 The free fatty acid linker binds albumin, which 
protects the peptide from DPP4 cleavage and 
reduces renal elimination 
Exenatide 
QW 
2011 53% Weekly 2.4 Reformulated version of exenatide 
encapsulated into micropsheres for slow 
plasma release 
Lixisenatide 2013 48%   Daily 3 Contains a modified version of exendin-4 to 
extend plasma half life 
Albiglutide 2014 95% Weekly 96-168 GLP-1 peptide–albumin fusion protein 
Dulaglutide 2014 90% Weekly 120 GLP-1 peptide–Fc fusion protein (peptibody) 
Semaglutide 2017 94% Weekly 168 GLP-1 peptide modified at positions 8 and 34 
with a free fatty acid linker at Lys26 
Semaglutide, 
oral 
2019 94% Daily 168 Co-formulation with the absorption enhancer 
sodium N-(8-[2-hydroxylbenzoyl] amino) 
caprylate. 
 
Data from GuidetoPharmacology3, DrugBank, Electronic Medicines Compendium and Clinicaltrials.gov (see 
Related links). 
Supplementary Text 
Insights from structural studies 
Currently experimental X-ray crystallography or cryo-electron microscopy (cryoEM) 
structures have been reported for the seven-transmembrane domain (7TM) domains of 62 
GPCRs, covering 212 distinct GPCR-ligand complexes and 200 unique ligands.  Structures 
of 27 peptide or protein binding GPCRs have been reported, covering 65 unique receptor-
ligand complexes. Twenty two of the experimentally determined GPCR structures (10%) 
contain a peptide ligand, covering Class A GPCRs apelin, angiotensin AT1  and AT2, 
complement C5a1, endothelin ETB, neurotensin NTS1,opioid receptors δ (DOR) and MOR, 
chemokine CCR5, CXCR4 and US28 receptors and Class B GPCRs calcitonin CT, CGRP,  
glucagon, GLP-1, and parathyroid PTH1 receptors (Supplementary Table 1, Figures 2 and 
4).  The Supplementary Table 1 and Supplementary Figure 1 show how the peptide bound 
structures of AT1, AT2, ETB, CT, DOR, MOR, CXCR4, CT, CGRP, glucagon, GLP-1 and 
PTH1 receptors provide structural templates and detailed insights into the structural 
determinants of ligand binding and functional activity (Box 3). This is shown for four identical 
and 21 homologous therapeutically relevant peptides, covering four of the 10 clinically 
relevant endogenous peptide ligands (Table 1), 15 of the 40 synthetic peptide drugs (Table 
2) and six of the 11 peptide ligands that are currently in development (Table 3).  The 
structures of several of the previously mentioned receptors, as well as neuropeptide NPYY1, 
KOR, NOP, CT and corticotropin releasing factor CRF1 receptors provide templates to model 
the three-dimensional binding modes of an additional 32 clinically relevant peptides to these 
and/or closely related receptors (Supplementary Table 1).  The accumulated portion of 
GPCR-peptide complexes that can be structurally modelled based on homologous peptides 
and/or receptors covers about half of all clinically relevant peptides reported in Tables 1, 2 
and 3.  The following section summarises the binding modes of these GPCR-peptide 
complexes (Supplementary Table 1, Supplementary Figure 1, Figures 2 and 4) providing 
insights into the structural determinants of binding and functional activity (Box 3) of several 
of these clinically relevant peptides and representing potential templates for the structure-
based optimisation and design of novel GPCR peptide therapeutics. 
Figures 2, 4 and Supplementary Figure 1 show how peptide ligands adopt diverse 
binding modes across GPCRs, reflecting the diverse chemical structures and properties of 
both ligands and receptor binding sites.  Class A GPCR peptide ligands generally target 
ECL2 and a polar/ionic interaction site at the top of TM6/7/ECL3 and bind differentially 
located and shaped lipophilic regions deeper in the 7TM receptor pocket.  Helical Class B 
GPCR ligands share an apolar interaction site with the region between TM1/2/7 that is less 
accessible in Class A GPCRs, but form differential polar interaction networks associated with 
different relative orientations of the extracellular N-terminal domain (ECD) and the 7TM 
domain1. 
The octapeptide Ang II [Sar1, Ile8] partial agonist bound AT1 and AT2 crystal 
structures122,123 show an extensive polar interaction network between Cter-K5x43, Tyr4-F/M45x52, 
His6/Pro7-R4.63x64, Arg2-D6x58/D7x31, whereas Ile1 and Pro7 target lipophilic hotspots between 
W2x60, V/L3x32 and I7.39x38 (Supplementary Table 1, Figures 2-3).  The conformation of Ang II 
[Sar1, Ile8] is stabilised by aromatic stacking between Tyr4 and His6 and an intramolecular H-
bond between Tyr4 and the C-terminus.  Comparative analysis of different conformational 
states of antagonist and agonist bound AT1 and AT2 structures (Supplementary Table 1), 
combined with biophysical and pharmacological studies provide insights into determinants of 
biased angiotensin receptor signalling (Box 3).  The homologous clinically relevant natural 
peptide angiotensin-II, Aclerastide (discontinued Phase 3) and TRV027 (discontinued Phase 
2) (Table 1, Table 3, Figure 2) likely adopt similar binding modes in AT1. 
The apelin receptor structure121(Figure 4) shows how the 17-amino acid apelin 
mimetic peptide agonist AMG3054 adopts binding mode targeting the major pocket in the 
7TM domain and the top of ECL 1 and ECL 2 (Supplementary Table 1, Figures 2 and 3, 
Supplementary Figure 1) and provides a structural template to identify determinants of 
biased apelin signalling (Box 3).  The C-terminal carboxylic acid group of the apelin mimetic 
interacts with the cationic R168ECL2 and K2686x55 residues.  The C-terminal chlorinated 
phenyl residue is stacked between Y351x39, W852x60, Y882x63, Y2997.43x42 and forms a halogen 
bond with the backbone carbonyl of W852x60. Nle15 binds another lipophilic region between 
Y2716.58 and F2907.34.  The identified structural determinants are consistent with apelin 
mutation studies121, showing the importance of for example of Y351x39, W852x60, and 
R168ECL2, suggesting that features of the AMG3504 binding mode are transferrable to apelin 
analogues. 
The endothelin ETB receptor structure125 shows how the C-terminus of the 21-residue 
endothelin-1 (ET-1) peptide targets lipophilic pockets in the major pocket of ETB, whereas 
the extra-cellular vestibule of the receptor folds around the α-helix and N-terminus of the 
peptide ligand (Supplementary Table 1, Figures 2 and 4, Supplementary Figure 1).  The C-
terminal carboxylic acid group of ET-1 forms a tight ionic H-bond interaction network with the 
cationic K1823x33, K2735.39x38, and R3436x55 residues, whereas the N-terminal Cys1 and Ser2 
residues form polar interactions with the backbone of L25745x52 in EL2.  The C-terminal Trp21 
and Ile20 residues of ET-1 bind a lipophilic pockets between TM5/6 (L2775.42x43, W3366x48, 
I3396x51) and TM2/3/EL1 (W16723x50, I1813x32 and Y1483x33.), respectively.  The conformation 
of ET is stabilised by disulfide bridges between the Cys1 and Cys15 and between Cys3 and 
Cys11.  The homologous shorter 14-mer SPI-1620 (discontinued Phase 2, Table 3, Figure 2) 
is expected to adopt a similar binding mode in ETA as the C-terminal region of ET-1 in the 
ETB structure, consistent with mutation studies125. 
The pentapeptide agonist DAMGO adopts a binding mode in the MOR cryoEM 
structure128 in which the N-terminal Tyr1 forms ionic interactions with D1473x32 and targets a 
small lipophilic region between I2966x51, H2786x52 and V2816x55 (Supplementary Table 1, 
Figures 2-3).  The MePhe4 residue of DAMGO targets a second lipophilic hotspot between 
W13323x50, P1433.28 and I1443x29.  The Tyr1 and Phe4 residues of the dual DOR/MOR 
pentapeptide agonist Met-enkephalin (Tyr1-Gly2-Gly3-Phe4-Met5, Ph2) Table 3, Figure 2) are 
expected to adopt a similar DOR/MOR binding mode as the Tyr1 and MePhe4 residues of 
DAMGO. 
The CXCR4 chemokine receptor structure (Supplementary Table 1, Figure 4)130 
shows how positively charged arginine residues of the cyclic 16-mer peptide antagonist 
CVX15 form ionic/H-bond interaction networks with CXCR4 (Arg1-D18745.51, Arg2-
T1173.33/D1714.61x60, Arg11-D2726x58/D2777.31x30), while the naphthalene moiety of Aln3 binds a 
lipophilic pocket formed by Y19045x54/F1995.39x38/H2035.42x43/I2596x55.  The beta-strand 
conformation of CVX15 is further stabilised by a disulfide bridges between the Cys4 and 
Cys13.  The homologous 15-mer BL-8040 (Phase 3, Table 3, Figure 2) is expected to adopt a 
similar binding mode in CXCR4, targeting an additional lipophilic pocket between W942x60, 
V1123x28, H1133x29 with its additional N-terminal 4-fluorinated benzyl residue, potentially 
forming additional intra/intermolecular ionic interactions with its C-terminal 
diaminopropoanoic acid residue.  The binding mode of CVX15/BL-8084 to CXCR4 is distinct 
from the binding mode of chemokine ligands which bind the receptor N-terminus with their 
conserved disulfide stabilised C-terminal region and target different lipophilic regions in the 
TM pocket2 as observed in CCL5 bound CCR5129 (Figure 3), vMIP-II bound CXCR4, and 
CX3CL1 bound US28132, 3 8 new crystal structures. 
The PMX53 bound C5a1 crystal structure124 shows how the C-terminal Arg6 residue 
of the discontinued (Phase 1A/2B) hexamer peptide antagonist PMX53 forms polar 
interactions with Y6x51 and D7.35x34, while the apolar Phe1 and dCha4/Trp5 residues target 
lipophilic regions between R264EL2/C27445x50/V27645x52 and between 
L2782x60/I1822x64/P1993x29/C27445x50/C3697.36x35, respectively (Figure 2, Figure 3). 
The peptidomimetic antagonist UR-MK299 forms H-bond interactions with Q2195x461, 
N2836x55 and D2866.58 and targets lipophilic regions between in the neuropeptide NPYY1 
crystal structure141(Figure 3), providing a structural template (Supplementary Table 1) for 
modelling the binding mode of the N-terminal Arg-Try residues of Obinepitide and TM30339 
(Table 3, discontinued Phase 2) in homologous NPYY2/NPYY4. 
Class B GPCRs comprise an ECD of 120–160 residues and a 7TM of 310–420 
residues.  In addition to the 7TM and full length (7TM and ECD) structures of class B GPCRs 
described below several structures of isolated class B GPCR ECDs have been 
solved149(Supplementary Table 1), including calcitonin analogue bound CT receptor144, GIP 
bound GIP receptor4 and GLP-1, Ex[9-39] and semaglutide bound GLP-1 receptor25,5,6.  
These ECD-peptide complexes show conserved hydrophobic interactions between 
conserved apolar residues in the C-terminal part of the ligand (such as GLP-1: Phe28, Ile29, 
Leu32) and similar hydrophobic interaction sites with the ECD of the corresponding receptor 
(for example, GLP-1 receptor: L32, T35, V36, and W39ECD in α1; Y69ECD in β turn 1 
connecting β1–β2; Y88, L89, and P90 in β turn 2 connecting β3–β4)149. 
The full-length calcitonin-like receptor (CLR) cryoEM structure shows how the C-
terminal region of the agonist CGRP binds the ECD, while the N-terminal helical region binds 
the 7TM domain of CLR133. The N-terminal Phe36 targets a hydrophobic pocket between 
G71ECD/W72ECD in CLR and W84/P85 of RAMP1. The CLR/CGRP/RAMP1 complex is further 
stabilised by amongst others polar interaction networks between N-terminal amide group of 
CGRP and T122ECD and between Lys35 (CGRP), R119ECD (CLR), and W84 (RAMP2), 
consistent with the function of RAMP1 as allosteric modulator of CLR. Val8 
(F3496x53/M3697x41/H3707x42/M3737x45) and Leu12/Leu16 (V1351X35/A1381x36/ 
L1391x37/L1411x39/F1421x40/L1952x68/a1992x72/H3707x42) in the C-terminal helix of CGRP target 
lipophilic regions in CLR, consistent with SAR and mutation studies showing the role of 
several of these residue in CGRP-peptide binding133 (Figure 3).  The CGRP bound CLR 
structure provides a structural basis for modelling the binding mode of several homologous 
clinically relevant peptides to CLR and/or CR receptors and RAMP bound AMY1/2/3 
complexes, including adrenomedullin, calcitonin, Davalintide, Elcatonin, and Pramlintide 
(Tables 1, 2, Supplementary Table 1 and Figure 2). 
The agonist 31-mer GLP-1, biased agonist 36-mer Ex-P5, and truncated agonist 15-
mer peptide 5 adopt a similar overall binding conformation and orientation within the 7TM 
domain of full-length GLP-1 receptor X-ray crystallography and cryoEM structures, but show 
different structural interaction patterns133,136,137,149(Figure 2 and 4, Supplementary Figure 1).  
Val3 and Val7 of Ex-P5 and the fluorinated Phe12 homolog X1 and the gem-dimethyl of 
peptide 5 target the same lipophilic pocket defined (L1411x36, L1441x39, Y1451x40, Y1481x43, 
L3847x38, E3877x41, L3887x42).  In the lower resolution GLP-1 bound cryoEM structure the 
homologous Phe12 and Val16 are located at a similar position, but TM1 seems to be 
rotated, with for example, L1441x39 and Y1481x43 towards the membrane.  The substituted 
biphenyl residue X2 of peptide 5 extends between TM1 (L1421x37/Y1451x40) and TM2 
(L2012x72/K2022x73), whereas the L-Norvalin derivative X3 of peptide 5 further extends 
between the ECD (L32), TM2 (M2042x75), ECL2 (C29645x50), targeting additional lipophilic 
regions to compensate for the limited interaction with the ECD and explaining the similar 
potency of peptide 5 compared to GLP-1.  Ex-P5 and peptide 5 share polar interactions with 
R29945x53 and R3807.35b, and form ligand specific polar interactions with Y1521x47/R1902x60 
(peptide 5/c-tetrazole-Ala), R3105.44 (Ex-P5/Glu1), and E3877.42b (peptide 5/Cap1) that are 
not observed in the GLP-1-bound GLP-1 receptor structure.  The binding modes of Ex-P5 
and peptide 5 are consistent with GLP-1 receptor peptide ligand SAR and mutation studies 
and provide a template for the elucidation of determinants of biased signalling (Box 3) and 
for modelling structural interactions of the clinically relevant peptides glucagon, GLP-1, 
Albiglutide, Dulaglutide, Exendin-4, Liraglutide. Lixisenatid, Semaglutide, GTP-010, 
Taspoglutide, TT-223 with the GLP-1 receptor (Tables 1, 2, 4 Supplementary Table 1, Figure 
2).  The GLP-1 receptor-peptide ligand complexes furthermore can serve as basis for the 
construction of GLP-2 (Apraglutide, Elsiglutide, Glepaglutide,Teduglutide) and GIP 
(MAR701, MAR709) in complex with homologous peptide ligands, guided by SAR and 
mutagenesis studies149 (Tables 1, 2, 4; Supplementary Table 1; Figure 2). 
The Ser2/Phe6 and Val10 residues of the partial agonist NNC1702 target the same 
lipophilic pockets defined by TM1 and TM7 (Y1381x36, F1411x39, Y1481x43, L3827x38, D3857x41, 
L3867x42) and TM1/TM2 (Y1381x36, L1982x72) in full-length glucagon receptor135 as the 
Ala8/Phe12 and Val16 homologs of GLP-1/Ex-P5/peptide 5 in the GLP-1 receptor structures 
described above. This glucagon receptor-peptide ligand binding mode is consistent with 
glucagon receptor ligand SAR and receptor mutation studies149. 
Also in the full-length PTH1 crystal structure139 and cryoEM structures140, ePTH 
(Aib3, Leu7) and PTH analogue (Ala3, Leu7), target the lipophilic pockets between TM1/2 
(F1841x36, L1871x39, C1911x43, M4417x38, E4447x41, M4457x42), in line with PTH1 SAR and 
mutation studies149.  The peptide bound PTH1 structures provide a template to model the 
interactions of PTH1/PTH2 receptors with PTH, PTHrP, Abaloparatide, Teriparatide, 
Ostabolin-C as well as the construction of homology models of GHRH with AKL-0707, 
DAC:GRs, Sermorelin, Tesamorelin (Tables 1, 2 and 4; Supplementary Table 1; Figure 2 
and 4; Supplementary Figure 1) 
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Supplementary Figure 1 │ X-ray crystallography and cryo-electron microscopy 
structures of GPCRs.  In the central GPCR phylogenetic tree peptide GPCRs for which 
7TM/full-length structures are available in complex with peptide ligands (red) or only in 
complex with non-peptide ligands (yellow) are distinguished from peptide GPCRs for which 
only ECD structures are available (green) and non-peptide GPCRs for which 7TM/full-length 
structures are available (blue), consistent with Table 5 (Supplementary).  Related GPCR 
families, Adhesion (purple), Glutamate (orange), Frizzled (light green) and Taste (dark 
green) are shown for reference.  Receptors are classified as orphans when the endogenous 
ligand(s) is not yet established.  The bottom panel summarises structural interactions for 
aligned binding site residues of class A and class B peptide GPCRs forming polar H-bond or 
ionic interactions (red), or only lipophilic interactions (grey) with peptide ligands shown in the 
individual binding mode figure panels. 
Binding sites of AMG3054 bound Apelin (PDB ID: 5VBL)121,, octapeptide Ang II [Sar1, Ile8] 
partial agonist bound angiotensin AT1 (PDB: 6DO1)122 Complement C5a1 (PDB: 6C1Q)124, 
Endothelin ETB (PDB: 5GLH)125, neurotensin NTS1R (PDB: 3ZEV) 126, UR-MK299 bound 
neuropeptide NPYY1 (PDB: 5ZBQ)141, MOR (PDB: 6DDE)128, chemokine CCR5 (PDB: 
5UIW)129 receptors, and class B GPCRs calcitonin Calcitonin gene-related peptide bound 
CGRP (PDB: 6E3Y)134, NNC-1702 bound glucagon receptor (PDB: 5YQZ)135, peptide 5 
(PDB: 5NX2)136 and Exendin-P5 (PDB: 6B3J)135 bound GLP-1 receptor, and ePTH bound 
parathyroid PTH1 139  receptors. Views are focused on the 7TM domain and consistent with 
the orientations of peptide diagrams shown in Figure 2. The binding pocket surfaces (grey 
mesh) are contoured at 1 kcal/mol using the C3 (carbon sp3) GRID probe203, whereas 
lipophilic areas are defined using the C1= (lipophilic) probe contoured at -2.8 to -3.0 
kcal/mol, customized to GPCR binding sites204. Generic GPCR residue numbers205 are 
provided based on Ballesteros-Weinstein Class A GPCR (Apelin, AT1, C5a1, CCR5, ETB, 
MOR, NPYY1)206 and Wootten207 Class B GPCR (CGRP, Glucagon, GLP-1, PTHR1) 
numbering schemes. According to these schemes, the first (1-7) denotes the 
transmembrane helix (TM), and the following number indicates the residue position relative 
to the most conserved amino-acid in the helix (which is assigned the number 50), 






































Supplementary Figure 2 │ 2D and 3D diagrams of clinically relevant GPCR peptides 
(Table 1) and synthetic GPCR peptide drugs (Table 2).  Peptides are shown as beads 
based on the three-dimensional position of Cα atoms of structural templates of peptides 
bound to experimentally determined 7TM structures of associated GPCRs (Supplementary 
Table 5).  The orientations of the 3D peptide bead strings are consistent with their binding 
mode in the GPCR binding site (Figure 3), assuming a view in which TM1 is on the left, TM5 
is on the right, and the extra-cellular side is up.  Peptides for which no 7TM GPCR structure 
bound 3D template is available, or depicted as 2D diagrams reflecting the putative structure 
based on (secondary) structure information of the free peptide, disulphide bridge constraints 
and binding mode information (showing an orientation consistent with the 3D diagrams). 
Supplementary Table 1| Experimentally determined structures of peptide binding GPCRs 
Family Target Receptor Ligand
 Ligand mode 
of action 
Similar peptide drug in 
Development PDB 
Class A      





ZD7155 ANT 4YAY196 
Ang II [Sar1,8Ile] AGO 6DO1122  
Angiotensin AT2 
8EM ANT None 5UNH
121  
8ES ANT 5UNF137; 5UNG  
Ang II [Sar1,8Ile]* AGO 
Angiotensin II 
Aclerastide (AT1), TRV120027 
(AT1) 
5XJM199  
Apelin Apelin AMG305 AGO Apelin 5VBL121 
Complement 
Peptide C5a1 











NDT 9513727 alloANT 5O9H 
Endothelin ETB 
Endothelin-1* AGO Endothelin 1, SPI-1620 5GLH; 5GLI125  
Bosentan ANT None 5XPR K-8794 ANT 5X93 
Neuropeptide Y Y1 BMS-193885 ANT None 5ZBH  UR-MK299 ANT 5ZBQ  
Neurotensin NTS1 NT(8-13)* AGO Neurotensin 4XEE; 4XES; 3ZEV
126; 4BUO; 4BV0; 4BWB; 4GRV; 
5T04 
opioid 
δ DIPP-NH2* ANT None 4RWA; 4RWD
127 
Naltrindole ANT 4N6H; 4EJ4 
κ MP1104 AGO None 6B73
142  





DAMGO* AGO 6DDE; 6DDF 128 





C-35 ANT 5DHG 
SB-612111 ANT 5DHH 
Orexin 
OX1 Suvorexant ANT 
None 
4ZJ8 
SB-674042 iAGO 4ZJC 
OX2 EMPA ANT 5WQC; 5WS3 Suvorexant ANT 4S0V 
Proteinase-
Activated 





AZ8838 ANT 5NDD 
Fab*  ANT 5NJ6 





CP-99,994 ANT 6HLL 
L760735 ANT 6E59 






NAM None 5T1A 
MK-0812 ANT 6GPS, 6GPX 
CCR5 Maraviroc ANT None 4MBS 
5P7-CCL5* AGO CCL3, CCL5 5UIW129  
CCR9 Vercirnon ANT None 5LWE 
CXCR4 
IT1t ANT None 3ODU; 3OE6; 3OE8; 3OE9130  
CVX15* ANT BL-8040 3OE0130  




4XT1*; 4XT3132  
CX3CL1.35* AGO 5WB2151  
Nb7$ AGO 5WB1151  
 Class B     
Calcitonin 
AM1 
Adrenomedullin* AGO Adrenomedullin 3AQF (ECD),  4RWF (ECD) 
CGRP analog* AGO CGRP 4RWG (ECD) 
CT Calcitonin* AGO Calcitonin, Elcatonin 5UZ7 5II0 (ECD)144 5UZ7a; 6NIY 
CGRP 
CGRP* AGO CGRP 6E3Y133  
Apo  None 3N7P (ECD) 
Telcagepant; 
Olcegepant ANT None 
3N7R (ECD) 
9968071l; 
Olcegepan ANT 3N7S (ECD) 
Corticotropin-
releasing factor 
CRF1 CRF* AGO CRF, Corticorelin 3EHU
148, 2L27 
CP-376395 NAM None 4K5Y*145; 4Z9G  
CRF2 




Urocortin-1*  AGO 1U34147  
































ZP3780* AGO  
NNC0640 
mAb1$ ANT 5XEZ; 5XF1
202 
mAb1$ ANT 4ERS (ECD) 
NNC0640a NAM 4L6R 









GTP-010, Taspoglutide,  
TT-223 
6B3J137 
GLP-1a* AGO 5VAI133  
Peptide 5* ANT 5NX2136  
GLP-1* AGO 3IOL (ECD)154  
Semaglutide* AGO 4ZGM (ECD)25  
Ex[9-39]* ANT 3C59 (ECD)153  
Exendin-4 
analog* AGO 5OTT (ECD) 
Exendin-4 
analog* AGO 5OTU (ECD) 
Exendin-4 
analog* AGO 5OTV (ECD) 
Exendin-4 
analog* AGO 5OTW (ECD) 
Fab 3F52$ ANT None 5E94 (ECD) 
NNC0640 NAM None 5VEX PF-06372222 NAM 5VEW 
 GIP GIP* AGO GIP, MAR701, MAR709 2QKH (ECD)152  
 GIP Gipg013 Fab$ ANT None 4HJ0 (ECD) 
 GHRH Apo  None 2XDG (ECD) 
Parathyroid 
Hormone PTH1 




PTH analog* AGO 6NBF; 6NBH; 6NBI140  
PTH* AGO 3C4M (ECD) 
PTHrP* AGO 3H3G (ECD) 
VIP and PACAP PAC1 
PACAP6–38* ANT 
None 
2JOD, 1GEA (ECD) 
Apo  3N94 (ECD) 
VPAC2 Apo  2X57 (ECD) 
a) Ligand included in crystallisation studies, but ligand coordinates not determined or low resolution (<4Å).  b) The following ligand types are 
defined: Full agonist (AGO), partial agonist (pAGO) inverse agonist (iAGO), antagonist (ANT) and negative allosteric modulators (NAM).  c) 
Peptide ligands are indicated with “P”, antibodies with (‘Ab’), other ligands are small molecules.  d) Endogeneous peptides and 
endogeneous/synthetic peptide drugs/in development indicated in Tables 1-3 that share sequence/structural similarity to the peptide ligand in 
the experimentally determined (X-ray crystallography, cryoEM, NMR) structure.  e) Assessment of structural receptor-peptide ligand models 
including endogeneous and/or clinically relevant peptide ligands (Table 1-3) that can be constructed by combining the specified structural 
templates (with indicated additional templates indicated between brackets).  f) Structures of truncated Extracellular Domain are indicated with 
‘ECD’ between brackets, other structures contain transmembrane domain.  Protein Data Bank200, 201 (PDB) ID codes of experimentally 
determined structures (crystallography, cryo-EM) of complexes of peptide ligands bound to the full-length transmembrane domain (TM-peptide) 
or extracellular domain (ECD-peptide) of the receptor, as well as non-peptide ligands bound to the receptor transmembrane domain (TM). 
Structures of free peptide ligands (NMR, crystallography) are only reported for receptors for which no peptide ligand structures are available. 
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Identification of endogenous peptides approved for clinical use was identified from the GuidetoPharmacology database. This has the most extensive 
classification with other groups being antibodies, natural products, metabolites or synthetic organics.  The list was compared with DrugBank with further 
information from RxList Global Data or relevant company websites. 
Supplementary Table 2| Endogenous peptides targeting Class A and B GPCRs that are approved for clinical use 























Class A          
Angiotensin AT1 AT2 
Angiotensin II 
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9.0 8-18  17.5 -  








Deficiency - - 90 5.4 Negligible 









- 5 8.4 - 
 
Note 1 
Pharmacokinetic and pharmacodynamics parameters were curated from GuidetoPharmacology, DrugBank as well as original citations.  The peptides 
identified in use in any geographical region, will largely reflect those used widely in major pharmaceutical markets such as North America, Asia and Europe 
but may not capture peptides licensed in just one country. 
Class, Target receptor and Ligand. Unlike small molecules that may target multiple receptors, the table reflects the consensus that peptides act primarily on 
a single receptor or family of receptors (such as the somatostatin family).  
Affinity and potency: Where a range of affinities and potencies were reported, these are shown. Where peptides have affinities for more than one subtype 
within the family, all values are shown where available. For example, the relative importance of the affinities for the five different subtypes of somatostatin 
receptors in the therapeutic action is unclear and all values have been included. Data are derived from human receptors except where indicated from rat†.  
pKi : negative logarithm to base 10 of the concentration of the competing ligand that would occupy 50% of receptors, determined in a competition binding 
assay. 
pKD : negative logarithm to base 10 of the equilibrium dissociation constant for ligand receptor interactions. 
pIC50 : negative logarithm to base 10 of the concentration of competing agonist or antagonist that inhibits the binding of a radioligand by 50% in a competition 
binding assay. 
pEC50 : the negative logarithm to base 10 of the molar concentration of an agonist that produces 50% of the maximal possible effect of that agonist. 
Plasma half-life (min) and route indicates calculations based on intravenous administration. Clinical administration may also be via other routes such as 
intra-muscular or intra-nasal that may alter these values. 
Volumes of distribution (L) have been recalculated where these were reported as litres/kg based on 70 kg body weight. 
Synonyms are given for clinical names of the peptide based on the information in databases indicated. 
Note 1. Human parathyroid hormone (1-84), manufactured as a recombinant form with the full 1-84 amino acids was approved for clinical use as Natpara, 
(ALX1-11,  rhPTH1-84) but it is included as shorter sequences are also effective in activating target receptors.  Teriparatide is a synthetic peptide comprising 
1-34 of the N-terminal amino acids of human parathyroid hormone. 
 
  
Supplementary Table 3 | Modified peptides targeting Class A and B GPCRs that are approved for clinical use 
Family Target Receptor 
Ligand 


























Class A            






































*1.33 - 15 - 
Proteolytic 
Enzymes 













Stimulation - - 
14.5 
*13-16 43.7 82 2.4 Renal, Biliary 
Antagon; Orgalutran; 





Cancer 8.8 - 
996-1690 










Hypogonadism. - - 0.16-0.67 - - - 
Metabolism 
by Hydrolysis 






Prostate Cancer 8.8 - 4.9 
44.1 
*13.7 27 7.3±2.5 Renal, Biliary 








*9.0-10.4 - *4 58 30 10.4  
Supprelin LA; Vantas; 






















































































































- 1.14 *528 16 - 23.7 
Billiary, 
Renal (<5%) 
DC 13-116; Somatuline; 







































BMY 41606; CCRIS 
6495;  
RC-160; Sanvar IR; 








Pre-Term Birth 6.0-7.6 - 1.7 18 l 46-48 41.8 
Proteolytic 
Enzymes 
ORF22164; RWJ 22164 
d[D-Tyr(Et)2, Thr4,Orn8] 
vasotocin 
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T2DM 8.7-9.0 **9.2 - *2.4 *28.3 - 9.1 Renal 
Exendin-4, AC002993; 
AC 2993; AC2993A; 




























Syndrome **Ϯ11.3 10 2.0 
7.2 









Osteoporosis **9.7 10.1 *1.7 50 
70 
(in vitro) - Renal BA058; Tymlos 






Parathyroidism - 4.6 
84 





Class, Target Receptor and Ligand.  Compilation of the data used the same databases and methods as outline in Table 1.  The table reflects the 
consensus that synthetic peptides act primarily on a single receptor or family of receptors (such as the somatostatin family).  Cyclosporin reported to be an 
antagonist of formylpeptide FPR1 receptor has been omitted as it is reported to interact with multiple targets and is not selective for a particular target. 
Clinical indication.  These represent the main clinical uses in DrugBank210, RxList211, Electronic Medicines Compendium213 and Clinical Trials.Gov214. 
Affinity and potency:  Where a range of affinities and potencies were reported, these are shown.  For peptides binding to somatostatin receptors, the 
relative importance of the affinities for the different subtypes in the therapeutic action is unclear and all values have been included.  Data are derived from 
human receptors except where indicated (Ϯ) where values at the rat receptor are reported. 
Plasma half-life (hr):  time taken for the concentration of a drug in plasma to decline to half its original level. 
Route: indicates calculations based on intravenous and sub-cutaneous administration.  Clinical administration for a small number of peptides may also be via 
other routes such as intra-muscular or intra-nasal and can alter these values.  For example, calcitonin (salmon) plasma half-lives are: intra-muscular, 0.96 hr, 
intra-nasal 0.3-38 hr. 
Volumes of distribution (L): Where values were reported as L/kg these have been recalculated based on 70 kg body weight. 
Plasma binding (%): The percentage of peptide bound to blood proteins including human serum albumin, lipoprotein, glycoprotein, and α, β‚ and γ globulins. 
Clearance (L/hr): Where values were reported as L/hr/kg, these have been recalculated based on 70 kg body weight. 
Route of Elimination: The main routes of metabolism and/or elimination are reported. 
Synonyms are given for clinical names of the synthetic peptide based on the information in databases indicated. 
NA: Not available 
Note 1. Abarelix was discontinued in United States in 2003, owing to allergic reactions but clinical use has continued in Europe. 
Note 2. Lutathera is a radiolabelled peptide that exploits radiation to kill tumours. 
Note 3. Withdrawn in United States. 
Note 4. Dulaglutide contains GLP-1(3- 37) with substitutions Ala8Gly, Gly22Glu, Arg36Gly, 16 amino acids  linker sequence and 228 amino acid synthetic 
human Fc fragment (immunoglobulin G4). Two identical peptide chains form a dimer, linked by inter-monomer disulphide bonds between Cys55-55 and 
Cys58-58. 
